Category: Health

  • MIL-OSI Security: Holiday Reminder on Federal Holiday Closures at NHB

    Source: United States Navy (Medical)

    Compiled by NHB/NMRTC Bremerton public affairs – With Christmas Eve officially declared as a federal holiday, the following adjustments will be in place at Naval Hospital Bremerton.

    NHB Urgent Care Clinic will be closed on the federal holidays of Christmas Eve and Christmas Day, Dec. 24 and 25, 2024.
    For those experiencing an actual life, limb or eyesight threatening emergency, call 911 or head to the nearest ER.
    The Nurse Advice Line is also available 24 hours a day, seven days a week to provide insight an guidance on dealing with many ailments. Nurse(s) on call will discuss concerns and provide recommendations for home treatment/care if applicable, and whether the issue should be addressed via an UCC or emergency department visit.
    The Nurse Advice Line’s toll-free number is 1 800 874 2273, and then select option one.

    NHB’s Pharmacy services at NHB, along with pharmacies at our branch health clinics on Naval Base Kitsap – Bangor and Naval Station Everett will [also] be closed on all federal holidays [Dec. 24-25, 2024].
    ScriptCenter is still available and open for all beneficiaries. The ScriptCenter Kiosk located in the “A” level parking garage lobby just before the elevator.
    Pickup is available 24 hours a day, 7 days a week.
    Patients can use Q-Anywhere via phone to text the words ‘Get in line’ to 1-877-909-2512 or use the Q-Anywhere link https://cxmlink.com/MTF1152 to start the process.
    When you text in, just click on the secure weblink to start the process.
    Just follow the provided directions to select the pharmacy, add the patients, select the pickup location and the priority of service.
    Please ensure to include the information about what you want us to fill, otherwise we will just process any new prescriptions submitted within the past two weeks.

    Shuttle Update – the Naval Hospital Bremerton – Madigan Army Medical Center shuttle will not be running Dec. 24-25, 2024.
    We will provide full schedule on December 26 and 31, 2024, as well as January 2, 2025.
    The service operates Monday-Friday – except federal holidays – and departs NHB by the UCC entrance at 7 a.m., 10 a.m., 1 p.m. and 4 p.m. The shuttle leaves Madigan by the Main Medical Mall north entrance at 8:30 a.m., 11:30 a.m., 2:30 p.m. and 5:30 p.m.

    MIL Security OSI

  • MIL-OSI USA: FDA Roundup: December 20, 2024

    Source: US Department of Health and Human Services – 3

    For Immediate Release:

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

    • Today, the FDA provided answers to a set of FAQs about software functions that may be described as clinical decision support (CDS). The FAQs are intended to help sponsors identify whether their CDS software may or may not meet the definition of a medical device, as described in the FDA’s final guidance for Clinical Decision Support Software. Additionally, the FDA updated the list of authorized Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices; totaling 1,016. The list is not a comprehensive resource of medical devices that incorporate AI/ML. The devices in this list have met the FDA’s applicable premarket requirements.
    • On Monday, the FDA approved a premarket approval application (PMA) 180-day supplement for the OraQuick Human Immunodeficiency Virus (HIV) Self-Test. This approval represents a labeling change to lower the approved age to individuals who are 14 to 17 years of age and older for the OraQuick HIV Self-Test to provide access to HIV testing to adolescents. The original approval of the OraQuick HIV -Self Test was indicated only for individuals who are 17 years and older.

      This is the first approval for an over-the-counter HIV test in adolescents. Availability will help in the detection of HIV among the adolescent population. 

      The OraQuick HIV Self-Test is a single home-use test to detect antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in human oral fluid specimens.  This test kit includes of a test stick (device) to collect the specimen, a test tube (vial) to insert the test stick (device) and complete the test, testing directions, booklet titled, “HIV, Testing and Me”, and access to the OraQuick Support Center to assist users with questions about performing the test, or to connect them with a healthcare provider in their area.

      The OraQuick HIV Self-Test is not intended to be used with specimens other than oral fluid. Individuals should obtain a confirmatory test in a medical setting.

      Complete instructions for use can be found on the FDA’s website here.

    • On Thursday, the FDA Office of Inspections and Investigations published a Viewpoint article titled Partnership in Action: Creating Safeguards for Imported Products Entering the United States in the Pacific Islands by Dan Solis, Assistant Commissioner for Import Operations. The article highlights the FDA’s work in Guam to ensure that imported products entering the U.S. through the Pacific Rim are safe for consumers. The Pacific Rim is a strategically significant location when it comes to ensuring the safety of products bound for consumers in the United States, as a little more than a third of global products coming into our country originate in the Asia-Pacific Region. You can learn more about the FDA’s efforts in the Pacific Islands by listening to OII Podcasts | FDA. The 5-Part series is called, Guam Series: FDA Presence and Impact in Pacific Islands.
    • On Thursday, the FDA updated the outbreak advisory for Salmonella Typhimurium infections linked to cucumbers with additional cases. The FDA’s investigation remains ongoing.
    • On Thursday, the FDA approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). FCS is a rare, genetic disorder that prevents the body from breaking down fats (TG) in the bloodstream. People with FCS can have TG levels in the thousands. These high TG levels can cause severe abdominal pain, inflammation of the pancreas (acute pancreatitis), and fatty deposits in the skin (xanthomas). Some of these symptoms, specifically acute pancreatitis, can be life-threatening. This is a first-in-class approval, meaning Tryngolza uses a new mechanism of action, or works differently in the body, than other therapies currently used to treat FCS.  The most common adverse reactions were injection site reactions, decreased platelet count, and arthralgia.
    • On Thursday, the FDA re-evaluated its determination from October 2, 2024, on the status of the tirzepatide shortage. The agency issued a new decision determining the tirzepatide injection shortage is resolved. The FDA’s determination is based on its analysis of all the information before the agency.  
    • On Wednesday, the FDA posted the latest video in the FDA In Your Day series. This one focuses on pertussis, also known as whooping cough, and what consumers can do to protect themselves and those around them.
    • On Wednesday, the FDA approved Ryoncil (remestemcel-L-rknd) an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy. The most common nonlaboratory adverse reactions (incidence ≥20%) were viral infectious disorders, bacterial infectious disorders, infection – pathogen unspecified, pyrexia, hemorrhage, edema, abdominal pain and hypertension.
    • On Wednesday, the FDA approved Ensacove (ensartinib, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. The most common adverse reactions (≥20%) were rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.
    • On Wednesday, the FDA shared our latest testing results for per- and polyfluoroalkyl (PFAS) substances in clams as follow up to the agency’s findings in the 2022 PFAS in seafood survey. Between October 2022 and September 2024, the FDA collected and analyzed 12 samples of processed clams with China as the country of origin. All 12 samples had detectable levels of at least one type of PFAS.
    • On Wednesday, the FDA issued a letter to food manufacturers that Amanita muscaria (A. muscaria), its extracts, and certain of its constituents (muscimol, ibotenic acid, and muscarine) are not authorized for use as ingredients in conventional food. A. muscaria and its constituents have been used in foods intended to have hallucinogenic effects, sometimes marketed as “psychedelic edibles”, “legal psychedelics” or “mushroom edibles”. After reviewing the available information about A. muscaria and its constituents, the FDA concluded that they do not meet the safety standard for use in food and that their use as food ingredients may be harmful. We also recommend that people avoid eating foods with these ingredients. The FDA’s assessment of chemicals in the food supply is part of our commitment to food safety and public health.
    • On Wednesday, the FDA updated the advisory for the outbreak of E. coli illnesses linked to certain sizes and brands of organic whole and baby carrots supplied by Grimmway Farms. According to CDC, as of December 18, 2024, this outbreak is over. The FDA conducted inspections at Grimmway Farms and collected environmental samples. Two environmental samples collected outside were positive for Shiga toxin-producing E. coli (STEC). Although both strains of E. coli detected in the samples are capable of causing human illness, neither match the strain of E. coli causing illnesses in this outbreak. The FDA is working with Grimmway Farms on corrective and preventive actions. The FDA’s investigation is complete.
    • On Tuesday, the FDA and the U.S. Department of Agriculture announced a charter that details how the two agencies work together to determine the appropriate agency to regulate the small number of animal biologicals for which jurisdiction may be unclear. Representatives from the FDA and USDA originally signed a Memorandum of Understanding in 2013 that outlined which animal biologicals each would regulate. Since 2013, science has continued to advance, and the jurisdiction of some products is not clear under the MOU. The charter includes a flowchart to help clarify which agency will regulate a given product, as well as information on how to request a jurisdiction determination from the FDA and USDA for animal biologicals.

    Related Information

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Consumer:
    888-INFO-FDA

    MIL OSI USA News

  • MIL-OSI Security: Dentist Sentenced to 15 Years in Prison for Stealing Drugs from Patients and Performing Surgery Without Proper Pain Management

    Source: Office of United States Attorneys

    SPRINGFIELD, Ill. – A Rochester, Illinois, dentist, Phillip M. Jensen, 64, was sentenced on December 18, 2024, to 15 years in prison for stealing fentanyl from his patients, injecting them with adulterated drugs, and performing surgery without proper pain management. Jenson also was ordered to pay a $200,000 fine.

    Jensen previously pleaded guilty to two counts of drug diversion, two counts of acquiring a controlled substance by fraud, one count of tampering with consumer products resulting in serious bodily injury, and two counts of false statements relating to health care matters in August 2024.

    Jensen, who prior to having his license suspended in 2022 had specialized in oral and maxillofacial surgery, started stealing fentanyl form his patients as early as December 2019. This conduct first came to light when his staff began noticing patients who were moving, moaning, and otherwise showing signs of pain and distress during surgery.

    Jensen admitted that he had stolen at least half of the fentanyl in every vial in the practice. He acknowledged removing the safety caps, withdrawing at least half of the fentanyl in the single-use vials, refilling the vials with saline, and gluing the caps back on to the vials. In a further effort to hide what he had done, Jensen made false entries into his surgical records claiming that he had given quantities of full-strength and unadulterated fentanyl to his patients to control their pain. He further billed both public and private insurance for these surgeries utilizing these same falsified records. In all, Jensen stole more than 40 grams of fentanyl for his personal use through his fraud.

    At the sentencing hearing before U.S. District Judge Colleen R. Lawless, the government presented evidence of Jensen’s lengthy history with addiction, his previous efforts at treatment, and his ultimate decision to prey upon his patients by stealing the drugs that were meant to provide them with comfort during their surgeries. The government presented evidence of the elaborate steps Jensen took to disguise his theft and how his theft of this necessary pain medication impacted his patients. 

    During the hearing, Judge Lawless also heard from several of the more than 99 identified victims of Jensen’s fraud, including the statement of a mother who discussed looking into the face of their child immediately following the surgery as the child cried and stated that they had “felt everything.” The government also presented the statement of a patient that awoke during her surgery. When Jensen realized she was awake, he struck the patient in the head with an instrument and completed the surgery, which involved the extraction of multiple teeth as well as the shaping and smoothing of the bones in her jaw, while she was conscious and lacking pain management.

    At the conclusion of the hearing, Judge Lawless rejected Jensen’s argument that he was less culpable than an average drug dealer. She noted that Jensen profited from his crimes. She also stated that while a dealer provides drugs to knowing and willing participants, Jensen provided diluted drugs without the consent or knowledge of his victims. She noted that Jensen was a physician who used his position of trust to hurt others. Judge Lawless concluded by asking, “If you cannot trust your doctor, who can you trust?”

    A federal grand jury returned an indictment against Jensen in February 2022 charging him with twenty felony counts. He was originally released on bond, but a warrant was issued in July 2024 for violation of the terms and conditions of bond after he stalked and harassed a potential witness in the case. Jensen was detained at that time, and he has remained in the custody of the U.S. Marshal Service.

    Judge Lawless, in imposing the fifteen-year sentence, rejected Jensen’s arguments for a lower drug weight and noted the egregious nature of his conduct. In addition to the $200,000 fine imposed, Judge Lawless also ordered Jensen to repay the government for the costs of the expert witness it had to hire. Jensen also lost his medical license as a result of his conduct.

    “This case represents the commitment of the Department of Justice, both in the Central District of Illinois and beyond, to protect and defend the public from those that would prey upon them,” said U.S. Attorney Gregory K. Harris. “People are never as vulnerable as when they place their faith in a health care provider to not only treat their condition but to administer anesthesia and pain medicine during that treatment. Jensen abused that faith and hurt others in the process. Because of this prosecution, Jensen will not be permitted to practice medicine again and will be prevented from hurting members of our community in the future.”

    “Health care professionals who tamper with patient medications create a risk of harm to patients, and also put at risk the trust that U.S. consumers have in those who provide their medical care,” said Ronne Malham, Special Agent in Charge of the Food and Drug Administration’s Office of Criminal Investigations Chicago Field Office. “We will continue to investigate and bring to justice health care professionals who take advantage of their unique medical positions and tamper with patients’ medications.”

    “Medical professionals who violate their oaths to ‘do no harm’ must be held accountable,” said Sheila Lyons, Special Agent in Charge of the U.S. Drug Enforcement Administration – Chicago Division. “The DEA will continue working to keep Illinois families safe from medical professionals who illegally divert opioid painkillers from legitimate medical supplies.”

    The United States Drug Enforcement Administration Diversion Unit, Springfield Resident Office, which focuses on cases involving pharmaceutical controlled substances diverted from the legal chain of commerce to the illegal drug market, investigated this case in conjunction with the Sangamon County Sheriff’s Office, the United States Food and Drug Administration, and the Illinois Department of Financial and Professional Regulation. Assistant U.S. Attorneys Douglas F. McMeyer and Sierra Senor-Moore represented the government in the prosecution.

    MIL Security OSI

  • MIL-OSI Europe: Text adopted – Amendment of Annex VI – Powers and responsibilities of the standing committees – P10_TA(2024)0064 – Wednesday, 18 December 2024 – Strasbourg

    Source: European Parliament

    The European Parliament,

    –  having regard to the proposal from the Conference of Presidents,

    –  having regard to its decision of 15 January 2014 on the powers and responsibilities of the standing committees(1),

    –  having regard to Rules 212, 218 and 219 of its Rules of Procedure,

    1.  Decides to set up a standing committee on Security and Defence and that the subcommittee on Security and Defence shall cease to exist; decides that the responsibilities of the committee on Foreign Affairs shall be amended accordingly;

    2.  Decides that the standing committee on Security and Defence shall be responsible for EU security and EU defence integration and cooperation including the issues related to the European Defence Agency, the permanent structured cooperation, the scrutiny of the common security and defence policy (CSDP), European Defence Industry and European defence industry funding where it contributes to the objectives of CSDP and related defence-exclusive measures of the European Union;

    3.  Decides to set up a standing committee on Public Health and that the subcommittee on Public Health shall cease to exist; decides that the name and the responsibilities of the committee on the Environment, Public Health and Food Safety shall be amended accordingly;

    4.  Decides that Annex VI to its Rules of Procedure is amended as follows:

    (1)  in Part I, paragraph 1, point 1 is replaced by the following:”‘1. the common foreign and security policy (CFSP);’”

    (2)  the following Part is inserted:”‘Ia. Committee on Security and Defence

    Committee responsible for the promotion, implementation and monitoring of the common security and defence policy (CSDP) and related defence-exclusive measures of the Union as envisaged in Article 42(2) of the Treaty on European Union, including:

       1. the developments threatening the territorial integrity of the Union and its Member States and the security of Union citizens;
       2. the capabilities and assets for civilian and military CSDP missions outside the Union, complementary measures under the European Peace Facility (EPF) as well as other budget lines and financial instruments directly supporting or contributing to the CSDP framework;
       3. the implementation and regular review of strategic defence decisions and policies;
       4. the progressive framing of a common Union defence policy leading to a Common Defence Union and the alignment of CSDP instruments with other Union financial instruments, legislation and policies;
       5. the capabilities to monitor and counter hybrid threats from outside the Union – including foreign information manipulation and interference (FIMI), cyber-defence, and related issues such as the protection of space assets, and the security of defence related critical infrastructure – within the limits of the CSDP and related defence-exclusive measures of the Union;
       6. the defence capabilities, preparedness and resilience of the Union and its Member States, including defence-specific research, development and innovation, joint production and life-cycle management;
       7. the measures, activities and instruments related to Union defence industrial integration and cooperation in pursuit of a single market for defence;
       8. the military mobility infrastructure relevant to the defence readiness of the Union and its Member States and the capacities to protect that infrastructure from foreign threats, except in relation to TEN-T-related projects and dual-use transport infrastructure, where, when appropriate, advice shall be provided to the responsible Committee on Transport and Tourism;
       9. the parliamentary oversight of defence-specific institutional Union structures and agencies, in particular:

       the Directorate-General of the EU Military Staff,
       the European Security and Defence College,
       the European Defence Agency (EDA),
       the Permanent Structured Cooperation (PESCO),
       the EU Satellite Centre within the limits of the CSDP and in establishing the European Defence Union, and
       the European External Action Service CSDP structure;
       10. initiatives, programmes and policies insofar as they aim to strengthen the European defence technological and industrial base and consolidate defence industrial cooperation aimed for exclusively military use by Member States and relevant Union capacities;
       11. defence-specific international agreements, depending on their content and scope, on security and defence, the external dimension of counter-terrorism, cyber defence, arms exports and control, disarmament and non-proliferation;
       12. relations with the Union’s security and defence partners, including NATO, the UN Department of Peace Operations, the Organization for Security and Co-operation in Europe (OSCE), and other international organisations, and with inter-parliamentary bodies for matters falling under the responsibility of the Committee on Security and Defence;
       13. political oversight and coordination with the work of the delegation for relations with the NATO Parliamentary Assembly and the possible future delegations with competences in the field of security and defence;
       14. multilateral frameworks for security, arms exports and control and non-proliferation issues, the external dimension of counter-terrorism, good practices to improve the effectiveness of security and defence, and the Union legal and institutional developments in those fields within the limits of the CSDP and related defence-exclusive measures of the Union;
       15. joint consultations, meetings and conferences on a regular basis to exchange information with the Council, the European External Action Service, and the Commission within the remit of the competences of the Committee on Security and Defence.’

    (3)  Part VIII is replaced by the following:”‘VIII. Committee on the Environment, Climate and Food Safety

    Committee responsible for:

       1. environmental and climate policy and protection measures, in particular concerning:

       (a) climate change, adaptation, resilience and preparedness,
       (b) environmental policy for the protection of public health,
       (c) air, soil and water pollution, waste management and recycling, noise levels and the protection of biodiversity,
       (d) chemicals, dangerous substances and preparations, pesticides and maximum residue levels, and cosmetics,
       (e) sustainable development,
       (f) international and regional measures and agreements aimed at protecting the environment,
       (g) restoration of environmental damage,
       (h) civil protection,
       (i) the European Environment Agency and the European Chemicals Agency;
       2. food safety issues, including in particular:

       (a) the labelling and safety of foodstuffs,
       (b) veterinary legislation concerning protection against risks to human health; public health checks on foodstuffs and food production systems,
       (c) the European Food Safety Authority and the Commission’s Directorate for Health and Food Audits and Analysis.’

    (4)  the following Part is inserted:”‘VIIIa. Committee on Public Health

    Committee responsible for public health matters related to:

       1. pharmaceuticals and medical devices;
       2. programmes and specific actions in the field of public health;
       3. health crisis preparedness and response;
       4. mental health and patients’ rights;
       5. health aspects of bioterrorism;
       6. the European Medicines Agency and the European Centre for Disease Prevention and Control;
       7. relations with the World Health Organization concerning the above matters.’

    5.  Decides that the standing committee on Security and Defence shall have 43 members and that the standing committee on Public Health shall have 43 members;

    6.  Decides that the standing committee on Security and Defence committee shall cooperate with other committees, guided by the principle of good and sincere cooperation, notably with the Committee on Foreign Affairs;

    7.  Decides, with reference to the decisions of the Conference of Presidents of 30 June 2019 and 9 January 2020 relating to the composition of committee and subcommittee bureaux, that the bureaux of the standing committee on Security and Defence and of the standing committee on Public Health may each consist of up to four vice-chairs;

    8.  Decides that this decision will enter into force on the first day of the next part-session;

    9.  Instructs its President to forward this decision to the Council and the Commission, for information.

    (1) OJ C 482, 23.12.2016, p. 160.

    MIL OSI Europe News

  • MIL-OSI Europe: Text adopted – Recommendation to the Council on the EU priorities for the 69th session of the UN Commission on the Status of Women – P10_TA(2024)0075 – Thursday, 19 December 2024 – Strasbourg

    Source: European Parliament

    The European Parliament,

    –  having regard to the UN declaration of 15 September 1995 entitled ‘Beijing Declaration and Platform for Action’ and the outcomes of its review conferences,

    –  having regard to the 1979 UN Convention on the Elimination of All Forms of Discrimination against Women,

    –  having regard to Articles 21 and 23 of the Charter of Fundamental Rights of the European Union,

    –  having regard to the UN 2030 Agenda for Sustainable Development, the principle of ‘leaving no one behind’ and, in particular, Sustainable Development Goal (SDG) 5, which seeks to achieve gender equality,

    –  having regard to the UN Secretary-General’s report of 13 December 2019 to the UN Commission on the Status of Women entitled ‘Review and appraisal of the implementation of the Beijing Declaration and Platform for Action and the outcomes of the twenty-third special session of the General Assembly’,

    –  having regard to the joint communication from the Commission and the High Representative of the Union for Foreign Affairs and Security Policy of 25 November 2020 entitled ‘EU Gender Action Plan (GAP) III: an ambitious agenda for gender equality and women’s empowerment in EU external action’ (JOIN(2020)0017) and the accompanying joint staff working document of 25 November 2020 entitled ‘Objectives and Indicators to frame the implementation of the Gender Action Plan III (2021-25)’ (SWD(2020)0284),

    –  having regard to the EU gender equality strategy for 2020-2025 of 5 March 2020,

    –  having regard to its resolution of 10 March 2022 on the EU Gender Action Plan III(1),

    –  having regard to the Committee on the Elimination of Discrimination against Women 2024 Inquiry concerning Poland, conducted under Article 8 of the Optional Protocol to the Convention,

    –  having regard to its resolution of 11 February 2021 on challenges ahead for women’s rights in Europe: more than 25 years after the Beijing Declaration and Platform for Action(2),

    –  having regard to the briefing entitled ‘Accelerating progress on Sustainable Development Goal 5 (SDG 5): Achieving gender equality and empowering women and girls’, published by its Directorate-General for Parliamentary Research Services on 18 September 2024,

    –  having regard to the UN Women and UN Department of Economic and Social Affairs report of September 2024 entitled ‘Progress on the Sustainable Development Goals: The Gender Snapshot 2024’,

    –  having regard to its resolution of 22 November 2023 on proposals of the European Parliament for the amendment of the Treaties(3),

    –  having regard to its resolution of 11 April 2024 on including the right to abortion in the EU Fundamental Rights Charter(4),

    –  having regard to Rule 121 of its Rules of Procedure,

    –  having regard to the report of the Committee on Women’s Rights and Gender Equality (A10-0030/2024),

    A.  whereas equality between women and men is a fundamental and universal principle of the EU, and whereas the EU’s external action must be guided by this principle, so that the EU continues to lead by example and further steps up and meets its commitments on gender equality;

    B.  whereas women’s and girls’ human rights and gender equality are not only fundamental human rights, but preconditions for advancing development and education and reducing poverty, and a necessary foundation for a peaceful, prosperous and sustainable world;

    C.  whereas 189 governments across the world, including the EU and its Member States, committed to working towards gender equality and empowering all women and girls at the 1995 Fourth World Conference on Women in Beijing;

    D.  whereas the Beijing Declaration and Platform for Action is the most comprehensive global agenda for promoting gender equality and is considered the international ‘Bill of Rights’ for women, defining women’s rights as human rights and articulating a vision of equal rights, freedom and opportunities for all women in the world, and was reaffirmed in 2015 with Goal 5, ‘Achieve gender equality and empower all women and girls’, of the sustainable development goals (SDGs) set out in the UN’s 2030 Agenda for Sustainable Development, by specifying targets and concrete measures across a range of issues affecting women and girls;

    E.  whereas the UN Assembly agreed in 2017 on a global indicator framework to standardise data collection, a key element for the comparability of data;

    F.  whereas just six years in advance of the 2030 deadline for the UN’s SDGs, not a single indicator under Goal 5 has been fully achieved; whereas the UN estimates that strong actions are needed in order to accelerate progress and to avoid taking 286 years to close gaps in legal protection and remove discriminatory legislation for women;

    G.  whereas gender equality is a cross cutting principle, to be mainstreamed across the SDGs;

    H.  whereas a 2024 UN study(5) on the evaluation of SDG 5 highlights that social norms still exist that legitimise gender-based violence against women and girls, without sufficient appropriate punishments against perpetrators, reduce access to health services, including sexual and reproductive health services, assign unpaid care and domestic work solely to women and restrict leadership opportunities; whereas women and girls can be still discriminated against through reproductive sex selection(6);

    I.  whereas the UN General Assembly has raised the alarm about the active resistance to achievements and advances in gender equality and the growing transnational backlash against women’s rights; whereas sexual and gender-based violence as well as anti-rights movements threaten the fundamental rights of women and girls on a daily basis; whereas there is a clear and urgent need to reaffirm, safeguard and develop gender equality and the human rights of women and girls(7);

    J.  whereas women’s sports competitions must be a celebration of sporting values; whereas all conditions must be met to ensure fairness within these competitions, to preserve the health of female athletes and to prevent physical and psychological violence against them;

    K.  whereas the Summit of the Future adopted document includes a specific action for achieving gender equality and the empowerment of all women and girls as a crucial contribution to progress(8);

    L.  whereas the rebels who brought down the regime in Syria are dominated by the Hayat Tahrir al-Sham (HTS) force; whereas the HTS group is an Islamist organisation classified as a terrorist organisation by the EU and the UN; whereas this situation raises serious concerns about the security of women and girls in the area;

    M.  whereas the UN’s Committee on the Elimination of Discrimination against Women, in an inquiry into Polish abortion law, has concluded that criminalising and restricting abortion discriminates against women;

    1.  Recommends that the Council:

       (a) re-confirm its full and unwavering commitment to the Beijing Declaration and Platform for Action and to the range of actions for human rights of women in all their diversity and gender equality outlined therein; confirm its commitment to human rights of women, including sexual and reproductive health and rights, through gender mainstreaming in all relevant policy areas and cycles, to the implementation of specific and targeted actions for human rights of women and gender equality, and to ensuring proper gender budgeting;
       (b) express its most profound opposition to the fact that Saudi Arabia is this year chair of CSW annual meeting and condemn any form of political instrumentation given that the country’s own record on women’s rights is abysmal and many of its policies contrary to the CSW’s own mandate and objectives; raise the systemic discrimination against women and persecution of women’s rights activists taking place in Saudi Arabia;
       (c) ensure that gender equality and women’s and girls’ rights are fully and proudly implemented as a core part of EU external action through an adequately funded, gender-responsive, inclusive and intersectional approach, taking into account marginalised women and women in vulnerable situations, especially as the funding of anti-gender movements globally is on the rise(9);
       (d) ensure the full involvement of Parliament and its Committee on Women’s Rights and Gender Equality in the decision-making process on the EU’s position at the 69th session of the UN Commission on the Status of Women (10-25 March 2025); ensure that Parliament has adequate, regular and timely information and access to the EU’s position document ahead of the negotiations; ensure the timely communication of Parliament’s position to the EU negotiating team; and further improve interinstitutional cooperation and informal consultation, including prior to and during negotiations, so that Parliament’s priorities are properly incorporated;
       (e) conduct an annual review of the progress, and setbacks, encountered in the implementation of the Beijing Declaration and Platform for Action;
       (f) pledge its strong support for the work of UN Women, which is a central actor in the UN system for advancing women’s rights, while committing to ensure its funding as well as increased finance for gender equality;
       (g) reinvigorate the EU’s efforts to overcome remaining challenges and accelerate the full implementation of the Beijing Declaration and Platform for Action, as it is a universal document, and EU Member States are far from having achieved all targets; ensure that the EU leads by example by putting in place robust policy measures, coupled with adequate financing to prevent, address and combat gender inequality in all its manifestations, empower women in all their diversity in all EU countries and ensure the realisation of their rights;
       (h) reiterate that the EU has an important role to play in achieving a gender-equal world through leading by example and supporting partner countries in addressing all types of direct and indirect discrimination and gender-based violence; recall the importance of the Istanbul Convention, urge the remaining five Member States that have still not ratified and implemented the Istanbul Convention to do so in the shortest possible timeframe, and also call on other countries to make progress towards signing and ratifying it;
       (i) press for equal access to and opportunities in all areas of life, to allow women in all their diversity to fulfil their potential, notably also in decision-making, including political, economic, financial, academic, health, cultural and sports-related, this also being essential for good governance and policymaking; encourage initiatives that promote female political leadership and participation, strengthening democratic practices and inspiring future generations of women;
       (j) within this context, express opposition to all forms of gender-based violence, including online or offline, as well as against women engaged in or wishing to engage in politics, which sustains and reinforces the invisibilisation of women and negative stereotypes about women and discourages women of all ages from entering politics and public spaces;
       (k) encourage measures that promote women’s participation and gender balance in all high impact sectors, including STEM; stress the importance of combating gender stereotypes, attitudes and prejudices in all their dimensions, through all kinds of media, including social media, and promote programmes, including through public-private partnerships, to reduce discrimination against women in politics and public positions;
       (l) emphasise that weak political guidance, lack of commitment, data gaps, insufficiently targeted investment, hate speech and hate campaigns, lack of access to relevant skills and knowledge, lack of economic opportunity and education, gender-related discrimination in the work place, including maternal mobbing, lack of economic autonomy and unequal conditions in the labour market, and the rise of anti-rights movements have been identified as obstacles and threats for women’s rights; thus making it necessary to encourage more women in politics and leadership, increase dedicated gender-equality-related investment in services such as education and health, and implement comprehensive rights-based and gender-responsive education, training and policy reforms to overcome these systemic structural barriers and achieve a truly equal society, for which the commitment and engagement of men and boys is essential;
       (m) apply gender mainstreaming and gender budgeting more consistently in all relevant EU policy areas, including external action, and lead by example in this regard, committing that the next MFF 2027 will include gender-equality-specific objectives and gender budgeting methods to be able to increase and monitor all investments regarding gender impact;
       (n) commit to constant appraisal and proactive corrective action in the EU’s internal and external policies in regard to gender equality, mainstreaming and budgeting;
       (o) defend and recall the importance of the Women Peace and Security (WPS) Agenda and the 25th anniversary of its landmark resolution, to renew the WPS EU action plan and to vocally combat any pushbacks towards this agenda internationally;
       (p) call on the Commission to further develop and roll out concrete and well-financed plans and actions to address the UN SDGs, specifically those related to gender equality, promoting equality in education;
       (q) take the lead in the global fight against the backlash against gender equality and women’s rights, generated in particular by increasingly influential anti-rights movements, by condemning all attempts to roll back, restrict or remove existing protections for gender equality, including on sexual and reproductive health and rights, as well as all forms of threats, intimidation and harassment, online and offline, of human rights defenders and civil society organisations working to advance these rights; emphasise that anti-gender movements are not only attacking women’s rights and gender equality but go hand-in-hand with anti-democratic movements; promote partnerships and alliances to counteract regressive movements and reaffirm the EU’s commitment to protecting gender equality as a core value, including by ensuring that women’s rights movements are adequately funded;
       (r) emphasise the need to protect and promote the rights of groups experiencing intersectional forms of discrimination, including people with disabilities and people who are from disadvantaged socio-economic backgrounds, racialised, from ethnic, minority or migrant backgrounds, older or LGBTIQ+, among others;
       (s) work to promote the concept of combating intersectional discrimination throughout all UN bodies and to conduct, apply and integrate intersectional gender analysis at different levels in the EU and its Member States;
       (t) urge the Commission to further develop and improve the collection of gender-disaggregated equality data on sex, race, colour, ethnic or social origin, genetic features, language, religion or other belief, political opinion, membership of a national minority, property, birth, disability, age or sexual orientation, sex characteristics and gender identity as well as geographically disaggregated data, including on a regional level, to ensure that this data contributes to better and more informed policymaking, and to reinforce the European Institute for Gender Equality both in terms of funding and capacity;
       (u) commit to advancing towards a foreign, security and development policy that gives priority to gender equality, protects and promotes the human rights of traditionally marginalised groups, such as transgender people, and takes into account the voices of women and LGBTIQ+ human rights defenders and civil society;
       (v) implement, without delay and to the fullest extent, the EU GAP III and ensure that 85 % of all new actions throughout external relations contribute to gender equality and women’s empowerment by 2027 at the latest;
       (w) take note of and implement the recommendations of Parliament’s resolution of 10 March 2022 on the EU GAP III, and thus prioritise GAP III in every aspect of EU external action through a gender-responsive and intersectional approach, both in terms of GAP III’s geographical coverage and areas of action, as well as gender mainstreaming in all areas of external action, whether trade, development policy, migration, humanitarian aid, security or sectors such as energy, fisheries and agriculture, while enhancing the consistency between the EU’s internal and external policies;
       (x) devise, fund and implement policies that combat the feminisation of poverty and reduce the role of gender as a factor in poverty both within and, through external action, outside of the EU, taking due note of intersectional factors, including sex, race, colour, ethnic or social origin, genetic features, language, religion or other belief, political opinion, membership of a national minority, property, birth, disability, age or sexual orientation, sex characteristics or gender identity;
       (y) advocate for equal access to resources and equal opportunities for women in all regions, to achieve economic empowerment and enable access to social justice and to a better quality of life as a result of a global vision of gender equality; recognise the unique challenges faced by women living in rural, remote and least developed areas, where access to resources, healthcare, education, and economic opportunities may be limited; call for targeted measures and investments that address the needs of these communities, through the promotion of gender equality, female entrepreneurship and employment opportunities or infrastructure; stress the importance of integrating these perspectives into all relevant external action and development strategies to ensure no woman is left behind;
       (z) address and monitor the systemic and root causes of female poverty with an emphasis on those in rural areas or isolated and disadvantaged areas, empower women and girls in all their diversity through education, training and lifelong learning, non-discriminatory labour opportunities, access to equal pay and pensions, and encourage employment programmes for women with disabilities;
       (aa) promote female entrepreneurship and women-led businesses through an enabling environment for their economic activities, such as support programmes in partner countries, ensuring equitable access to business opportunities and training in entrepreneurial skills;
       (ab) encourage initiatives that strengthen women’s economic autonomy and job creation in high-growth sectors, support initiatives that empower women economically, particularly women entrepreneurs and those leading micro, small and medium-sized enterprises, as well as fight stereotypes and combat persisting inequalities in education, as well as addressing women’s employment rate and under-representation in certain sectors like STEM and AI;
       (ac) ensure access to social services, including family support services, equal shares of unpaid care and social responsibilities through legislative initiatives, efforts to combat harmful gender stereotyping, patriarchal attitudes and systems and promote women as role models, and work-life-balance policies that ensure access to digital education and skills training to bridge the digital gender divide; enable women’s access to ownership, property, adequate and affordable housing and land, eliminating barriers, with focus on addressing the specific needs of women, in particular those in poverty and female-led households;
       (ad) call for further efforts, legislation and enforcement of existing measures to ensure the rights of women care workers and domestic workers as well as the recognition of informal carers, including single mothers, recognising their work as essential for making our society function; push for more ambitious care policies and investments in care with a view to advancing towards care economies, setting minimum standards and guidelines for care throughout the life cycle, with an intersectional perspective;
       (ae) develop labour migration policies and programmes that are gender-responsive, including in highly ‘feminised’ and informal sectors such as domestic and care work, and which address the gendered barriers to women’s labour force participation and skills recognition;
       (af) encourage, in the EU, the right to asylum, and the recognition, protection, support and integration of women who are victims of violence, whatever the form;
       (ag) enhance the EU’s response, resources and toolkit, both internally and externally, regarding online and offline gender-based violence, including domestic, sexual, physical, psychological, verbal and economic violence, harassment at work, as well as violence in situations of conflict and war, trafficking, early and forced marriages and sexual and reproductive exploitation, noting that this should include support for the establishment of help centres for women victims of violence in non-EU countries, particularly in disadvantaged areas, similar to anti-violence centres, with a dual objective, namely: assisting in the recognition of situations of violence and providing both legal and practical protection and support for women who decide to report and exit violence;
       (ah) advocate for a consent-based definition of rape as a universal standard across all regions, aiming to enhance legal protections and ensure that sexual violence is defined by the absence of consent, rather than solely by the use of force;
       (ai) highlight the major impact of online gender-based violence on women’s and girls’ personal and professional lives, and on their mental and physical health;
       (aj) underline the importance of enforcing international humanitarian law to safeguard the rights of women and girls in conflict; ensure that external agreements, including those related to border control and cooperation with non-EU countries, prioritise the safety of women and girls, stressing that the EU must ensure that partner countries uphold high human rights standards, particularly in preventing gender-based violence including trafficking for the purpose of sexual exploitation;
       (ak) pay particular attention to the condition of Syrian women and children, including those from Christian minorities, who are more likely to be the particular target of an Islamist regime, as already seen in several Middle Eastern countries, such as Afghanistan and Iraq;
       (al) promote the prevention of gender-based violence in sports by establishing a system to monitor and prevent such violence within sports institutions, requiring organisations to adopt preventive policies and measures, along with a secure and protected reporting mechanism;
       (am) remove the legal, financial, social and practical barriers and restrictions on access to safe and legal abortion worldwide; advocate firmly for the defence of sexual and reproductive health and rights as fundamental rights and fight against anti-choice networks; ensure that women and girls in all their diversity have information and access to affordable health services, including for sexual and reproductive health and rights, in line with international human rights and public health standards, including comprehensive age-appropriate and scientifically accurate sexuality and relationship education, access to contraception and emergency contraception, safe and legal abortion, respectful maternal healthcare and care-based health services; ensure that women are protected from forced pregnancies and sex-selective or forced abortions, particularly in the context of ethnic cleansing practices, and that in no case should abortion be promoted as a method of family planning, as mentioned in the Beijing Declaration; emphasise the importance of access to mental health services tailored to the specific needs of women and girls;
       (an) promote dignified and human rights-respectful conditions for incarcerated women who are also mothers, with special attention to the needs of mothers with young children; support access to healthcare, psychological care and rehabilitation programmes, ensuring adequate spaces to maintain the bond with their children;
       (ao) take note of and implement the recommendations of the European Parliament’s resolution of 11 April 2024 on including the right to abortion in the EU Fundamental Rights Charter;
       (ap) commit to increase efforts to address gender issues in the context of the green and energy transition, recognising that the climate crisis is not gender-neutral; acknowledge the intersectional and disproportionate impact of climate change on women and girls, particularly in developing countries, as well as in the regions and rural areas most affected by these changes; advocate for the inclusion of women in environmental decision-making processes to build resilience and gender-responsive strategies;
       (aq) advocate for and strengthen civil society organisations working to advance women’s and girls’ rights and gender equality in all circumstances including disability, violence, discrimination in the workplace or motherhood; advocate for the provision of safe spaces and shelters for women and girls suffering violence or threats; ensure the protection of human rights defenders, and their participation in the relevant forums;
       (ar) work to ensure that grassroots organisations and women’s and LGBTIQ+ rights defenders, especially small organisations, are supported through the provision of adequate funding and the removal of restrictions that impede their ability to operate; provide targeted measures and capacity-building support to grassroots women’s organisations to amplify their impact at the local and international levels; actively work against initiatives aimed at diminishing the civic space globally;
       (as) establish a Council Configuration on Gender Equality and Equality, to create a formal forum for the ministers responsible for the matters of equality to foster cooperation, coordinate policies and exchange best practices among Member States;

    2.  Instructs its President to forward this recommendation to the Council, and for information, to the Commission.

    (1) OJ C 347, 9.9.2022, p. 150.
    (2) OJ C 465, 17.11.2021, p. 160.
    (3) OJ C, C/2024/4216, 24.7.2024, ELI: http://data.europa.eu/eli/C/2024/4216/oj.
    (4) Texts adopted, P9_TA(2024)0286 .
    (5) UN, ‘Are we getting there? A synthesis of UN system evaluations of SDG 5’, March 2024, https://www.unwomen.org/en/digital-library/publications/2024/03/are-we-getting-there-a-synthesis-of-un-system-evaluations-of-sdg-5.
    (6) Office of the High Commissioner for Human Rights, UN Population Fund, UN Women, UNIFCEF, World Health Organization, ‘Preventing gender-biased sex selection: an interagency statement’,2011, https://www.unfpa.org/sites/default/files/resource-pdf/Preventing_gender-biased_sex_selection.pdf
    (7) UN General Assembly, ‘Escalating backlash against gender equality and urgency of reaffirming substantive equality and the human rights of women and girls: Report of the Working Group on discrimination against women and girls’, 15 May 2024, https://documents.un.org/doc/undoc/gen/g24/073/47/pdf/g2407347.pdf. .
    (8) UN, ‘Summit of the Future outcome documents: Pact for the Future, Global Digital Compact and Declaration on Future Generations’, September 2024, https://www.un.org/sites/un2.un.org/files/sotf-pact_for_the_future_adopted.pdf.
    (9) Datta, N., European Parliamentary Forum for Sexual and Reproductive Rights, ‘Tip of the Iceberg– Religious Extremist Funders against Human Rights for Sexuality and Reproductive Health in Europe 2009 – 2018’ June 2021, https://www.epfweb.org/sites/default/files/2021-08/Tip%20of%20the%20Iceberg%20August%202021%20Final.pdf.

    MIL OSI Europe News

  • MIL-OSI Security: IAEA Year in Review 2024

    Source: International Atomic Energy Agency – IAEA

    IAEA scientists taking samples in Antarctica as part of a 2024 research mission to study the impact of plastic pollution on the region and its inhabitants. 

    In 2024, the IAEA advanced its research and development efforts across diverse applications of nuclear science.

    The Zoonotic Disease Integrated Action (ZODIAC) initiative expanded its reach, equipping nearly 40 veterinary laboratories with cutting-edge diagnostic tools and training over 1000 professionals across 130 countries. With 129 national laboratories now part of its network, ZODIAC fosters international collaboration through its dedicated portal.

    Cancer remains a leading cause of death globally, yet nearly half of all patients lack access to radiotherapy. To address this, the IAEA’s Rays of Hope initiative expanded its network of Anchor Centres to 11, and supported a Lancet Oncology Commission which published a comprehensive roadmap outlining strategies to address global radiotherapy gaps, improve access and reduce the cancer burden worldwide.

    NUTEC Plastics achieved groundbreaking research results, confirming microplastics in Antarctica through a study with Argentine research stations, supported by the IAEA’s Monaco Marine Environment Laboratories. The initiative expanded its 100-country laboratory network, driving global plastic pollution monitoring and research. It also advanced innovative solutions, using ionizing radiation to develop bio-based plastics, reducing reliance on petroleum-based materials and cutting greenhouse gas emissions.

    The IAEA also developed methods to verify the authenticity of foods with specific geographic origins, by using stable isotope analysis to identify cases of fraud. This breakthrough enhances food authenticity and integrity in global markets.

    In agriculture, advanced diagnostic assays developed by the Agency’s Plant Breeding and Genetics Laboratory provide rapid, reliable, and resource-efficient tools for disease detection, addressing challenges exacerbated by climate change.

    Since its launch in 2023, Atoms4Food has supported agrifood transformation through innovations in cropping systems, livestock productivity, and natural resource management. Through the Joint FAO/IAEA Centre, a roadmap for a protein digestibility database was developed to guide evidence-based dietary policies.

    The Agency is also advancing industrial 3D printing by using non-destructive testing techniques like X rays and gamma computed tomography scans to ensure the quality and safety of 3D-printed components, supporting industries with more reliable production processes.

    The Global Network of Water Analysis Laboratories (GloWAL) completed its baseline survey in 2024, involving 85 laboratories from 65 countries. The results will inform capacity-building efforts in isotope hydrology, with a focus on regional networks, including a Latin America-led initiative starting in 2025.

    Upcoming in 2025: In 2025, the IAEA will continue advancing key global initiatives aimed at addressing some of the most pressing development challenges facing countries today. Rays of Hope, working closely with Anchor Centres, will enhance cancer care through regional capacity-building. Additionally, the development of the SUNRISE database will contribute to advancing radiation medicine, enabling policymakers and practitioners to leverage insights that strengthen cancer care worldwide. ZODIAC will expand its network and focus on disease forecasting, particularly zoonotic and climate-related health risks. NUTEC Plastics will address plastic pollution with upcycling technology and expand its marine microplastic monitoring network. Atoms4Food will scale nuclear technologies to improve food security and support climate-resilient crops, alongside its work on a protein digestibility database. GloWAL will continue to focus on capacity-building in isotope hydrology. The ReNuAL2 laboratory upgrades will strengthen the IAEA’s role in addressing food, health, and environmental challenges.

    MIL Security OSI

  • MIL-OSI United Nations: Sudan’s El Fasher siege: UN humanitarians killed as refugee crisis intensifies

    Source: United Nations 4

    Peace and Security

    The ongoing conflict in Sudan – particularly around besieged El Fasher – and a growing refugee crisis on the South Sudan border, have intensified an already alarming humanitarian crisis, according to UN agencies on Friday. 

    In a new report, the UN human rights office (OHCHR) has detailed the catastrophic humanitarian situation unfolding in El Fasher, the capital of Sudan’s North Darfur state.

    The city has been under siege for seven months by fighters from the powerful militia known as the RSF, which has been battling Government forces for control of Sudan since April last year. Thousands of civilians are trapped, leaving at least 782 civilians dead and over 1,143 injured.

    The continuing siege of El Fasher and the relentless fighting are devastating lives everyday on a massive scale,” said UN High Commissioner for Human Rights Volker Türk.

    The report, based on 52 interviews conducted in October and November with survivors who fled El Fasher, reveals a widespread use of explosive weapons in populated areas by the Rapid Support Forces and Sudanese Armed Forces (SAF) – together with their allied militias.

    These actions raise serious concerns about violations of international humanitarian law, including potential war crimes.

    Hospitals and camps targeted

    The report highlights attacks on key civilian infrastructure, including hospitals and camps for internally displaced persons (IDPs).

    The Al-Saudi Maternity Hospital, the last remaining public hospital in El Fasher providing surgical and reproductive health services, has been repeatedly shelled by the RSF.

    Tumbasi Medical Centre was similarly targeted in August, resulting in the deaths of 23 people and injuries to 60 more.

    The report also documents increased cases of sexual violence since the siege began, exacerbating the suffering of vulnerable populations.

    The Zamzam IDP camp, located 15 km south of El Fasher and home to hundreds of thousands of displaced people, has been shelled six times by the RSF, reportedly killing at least 15 civilians.

    Attacks against the civilian population and protected persons and objects, including medical facilities, may amount to war crimes,” said Li Fung, the UN High Commissioner’s Representative in Sudan.

    Risk of escalation

    The situation in El Fasher remains dire, with the report warning of potential large-scale attacks on Zamzam camp and the city itself

    Any large-scale attack on Zamzam camp and El Fasher city will catapult civilian suffering to catastrophic levels,” Mr. Türk cautioned.

    Rights office, OHCHR, has called on all parties – as well as the international community – to engage in mediation efforts and immediately end hostilities.

    © UNHCR/Reason Moses Runyanga

    Families arrive at a transit centre in Renk, South Sudan, after fleeing escalating violence in Sudan.

    WFP workers killed

    The World Food Programme (WFP) mourned the deaths of three staff members in the Blue Nile state, killed during an aerial bombardment on 19 December.

    WFP Executive DirectorCindy McCain condemned the attack, calling for accountability.

    Any loss of life in humanitarian service is unconscionable. Humanitarians are not, and must never be, a target,” Ms. McCain gravely stated.

    “2024 is the deadliest year on record for aid workers in Sudan. Yet despite significant threats to their personal safety, they continue to do all they can to provide vital support wherever it is needed,” underscored Secretary-General António Guterres in a statement released by his spokesperson.

    Refugee crisis at the border

    Meanwhile, the spillover from the war between rival militaries is overwhelming neighbouring South Sudan.

    UNHCR warns that over 80,000 people have fled into South Sudan in just three weeks, joining the more than one million Sudanese refugees already there.

    The recent surge in arrivals in South Sudan is overwhelming services in border areas, and funding for the humanitarian response remains insufficient,” said Marie-Helene Verney, UNHCR Representative in South Sudan.

    Call for accountability

    The UN is calling for a renewed push for mediation and increased international support to prevent further civilian suffering.

    Ms. Fung expressed the need for accountability and compliance with international law particularly due to “the Jeddah Declaration of Commitments that was signed by both parties in May 2023.”

    The OHCHR report also underscores the urgent need for a thorough investigation into potential war crimes and for those responsible to be held accountable.

    Emergency funds for Egypt

    The Emergency Relief Coordinator, Tom Fletcher, has allocated $6 million from the UN’s Central Emergency Response Fund (CERF) to address the humanitarian needs of refugees fleeing conflict in Sudan to Egypt, in support of the ongoing response there.

    The conflict in Sudan has created the world’s fastest-growing displacement crisis, the UN Spokesperson Stéphane Dujarric told reporters on Friday.

    “Of the more than three million people who have sought protection across Sudan’s borders since April of last year, some 1.2 million are being hosted by Egypt – more than in any other country – according to recent data from the Egyptian Government,” he told reporters at the daily briefing in New York. 

    MIL OSI United Nations News

  • MIL-OSI USA: Dentist Sentenced to 15 Years in Prison for Stealing Drugs from Patients and Performing Surgery Without Proper Pain Management

    Source: US Department of Health and Human Services – 3

    Department of Justice
    U.S. Attorney’s Office
    Central District of Illinois

    FOR IMMEDIATE RELEASE
    Friday, December 20, 2024

    SPRINGFIELD, Ill. – A Rochester, Illinois, dentist, Phillip M. Jensen, 64, was sentenced on December 18, 2024, to 15 years in prison for stealing fentanyl from his patients, injecting them with adulterated drugs, and performing surgery without proper pain management. Jenson also was ordered to pay a $200,000 fine.

    Jensen previously pleaded guilty to two counts of drug diversion, two counts of acquiring a controlled substance by fraud, one count of tampering with consumer products resulting in serious bodily injury, and two counts of false statements relating to health care matters in August 2024.

    Jensen, who prior to having his license suspended in 2022 had specialized in oral and maxillofacial surgery, started stealing fentanyl form his patients as early as December 2019. This conduct first came to light when his staff began noticing patients who were moving, moaning, and otherwise showing signs of pain and distress during surgery.

    Jensen admitted that he had stolen at least half of the fentanyl in every vial in the practice. He acknowledged removing the safety caps, withdrawing at least half of the fentanyl in the single-use vials, refilling the vials with saline, and gluing the caps back on to the vials. In a further effort to hide what he had done, Jensen made false entries into his surgical records claiming that he had given quantities of full-strength and unadulterated fentanyl to his patients to control their pain. He further billed both public and private insurance for these surgeries utilizing these same falsified records. In all, Jensen stole more than 40 grams of fentanyl for his personal use through his fraud.

    At the sentencing hearing before U.S. District Judge Colleen R. Lawless, the government presented evidence of Jensen’s lengthy history with addiction, his previous efforts at treatment, and his ultimate decision to prey upon his patients by stealing the drugs that were meant to provide them with comfort during their surgeries. The government presented evidence of the elaborate steps Jensen took to disguise his theft and how his theft of this necessary pain medication impacted his patients.

    During the hearing, Judge Lawless also heard from several of the more than 99 identified victims of Jensen’s fraud, including the statement of a mother who discussed looking into the face of their child immediately following the surgery as the child cried and stated that they had “felt everything.” The government also presented the statement of a patient that awoke during her surgery. When Jensen realized she was awake, he struck the patient in the head with an instrument and completed the surgery, which involved the extraction of multiple teeth as well as the shaping and smoothing of the bones in her jaw, while she was conscious and lacking pain management.

    At the conclusion of the hearing, Judge Lawless rejected Jensen’s argument that he was less culpable than an average drug dealer. She noted that Jensen profited from his crimes. She also stated that while a dealer provides drugs to knowing and willing participants, Jensen provided diluted drugs without the consent or knowledge of his victims. She noted that Jensen was a physician who used his position of trust to hurt others. Judge Lawless concluded by asking, “If you cannot trust your doctor, who can you trust?”

    A federal grand jury returned an indictment against Jensen in February 2022 charging him with twenty felony counts. He was originally released on bond, but a warrant was issued in July 2024 for violation of the terms and conditions of bond after he stalked and harassed a potential witness in the case. Jensen was detained at that time, and he has remained in the custody of the U.S. Marshal Service.

    Judge Lawless, in imposing the fifteen-year sentence, rejected Jensen’s arguments for a lower drug weight and noted the egregious nature of his conduct. In addition to the $200,000 fine imposed, Judge Lawless also ordered Jensen to repay the government for the costs of the expert witness it had to hire. Jensen also lost his medical license as a result of his conduct.

    “This case represents the commitment of the Department of Justice, both in the Central District of Illinois and beyond, to protect and defend the public from those that would prey upon them,” said U.S. Attorney Gregory K. Harris. “People are never as vulnerable as when they place their faith in a health care provider to not only treat their condition but to administer anesthesia and pain medicine during that treatment. Jensen abused that faith and hurt others in the process. Because of this prosecution, Jensen will not be permitted to practice medicine again and will be prevented from hurting members of our community in the future.”

    “Health care professionals who tamper with patient medications create a risk of harm to patients, and also put at risk the trust that U.S. consumers have in those who provide their medical care,” said Ronne Malham, Special Agent in Charge of the Food and Drug Administration’s Office of Criminal Investigations Chicago Field Office. “We will continue to investigate and bring to justice health care professionals who take advantage of their unique medical positions and tamper with patients’ medications.”

    “Medical professionals who violate their oaths to ‘do no harm’ must be held accountable,” said Sheila Lyons, Special Agent in Charge of the U.S. Drug Enforcement Administration – Chicago Division. “The DEA will continue working to keep Illinois families safe from medical professionals who illegally divert opioid painkillers from legitimate medical supplies.”

    The United States Drug Enforcement Administration Diversion Unit, Springfield Resident Office, which focuses on cases involving pharmaceutical controlled substances diverted from the legal chain of commerce to the illegal drug market, investigated this case in conjunction with the Sangamon County Sheriff’s Office, the United States Food and Drug Administration, and the Illinois Department of Financial and Professional Regulation. Assistant U.S. Attorneys Douglas F. McMeyer and Sierra Senor-Moore represented the government in the prosecution.

    MIL OSI USA News

  • MIL-OSI Asia-Pac: “JAM(Jan Dhan, Aadhar, Mobile)TRINITY and digital revolution: A Decade of Financial Inclusion, Transparency and Corruption Free India”

    Source: Government of India

    “JAM(Jan Dhan, Aadhar, Mobile)TRINITY and digital revolution: A Decade of Financial Inclusion, Transparency and Corruption Free India”

    Ayushman Bharat: Path towards an Inclusive Healthcare Paradigm

    There are more than 54 crore Jan Dhan Yojana accounts, with a total deposit balance of approximately ₹2.39 lakh crore- an increase of over 15 times since its inception.

    37.02 crore RuPay cards have been issued to PMJDY account holders

    In FY 2023-24, UPI transactions reached ₹200 lakh crore, a 138% increase from 2017-18.

    UPI now operational in seven countries and more than 40% of the global real-time payment transactions are happening in India.

    As on 30.11.2024, approximately 36 crore Ayushman cards have been created across the country and a total of around 29,929 hospitals are empaneled under the scheme including 13,222 private hospitals

    AB-PMJAY is presently implemented in 33 States/UTs across the country.

    Posted On: 20 DEC 2024 7:29PM by PIB Delhi

    Modi Government has been working for the poor and more than 200 schemes have been launched in the last 10 years for the welfare of the 140 crore people of the nation, said Union Minister of State for Corporate Affairs and Road, Transport and Highways,Shri Harsh Malhotra. Shri Malhotra was addressing a Press Conference on impact of path breaking reforms of JAM(Jan Dhan Yojna, Aadhar& Mobile) Trinity Schemes,Digital Transactions and AYUSHMAN BHARAT-PM JAY.

    Shri Malhotra stated that under the visionary leadership of PM Shri Narendra Modi, Pradhan Mantri Jan Dhan Yojana (PMJDY) has solved a significant portion of India’s population by bringing them into the banking ecosystem.  At present, there are more than 54 crore accounts, with a total deposit balance of approximately ₹2.39 lakh crore- an increase of over 15 times since its inception. The scheme has been particularly successful in rural ,semi-urban areas and amongst women, with around 66% of accounts coming from these regions. Furthermore, 37.02 croreRuPay cards have been issued to PMJDY account holders, with the average deposit per account rising significantly, reflecting increased usage and savings behaviour. The World Bank has also acknowledged that India has achieved its financial inclusion goals in just six years, a feat that would have taken 47 years without its advanced Digital Public Infrastructure. 
     

    PM-Jan Dhan Yojna  coupled with JAM Trinity has become the world’s largest Financial inclusion program. Now, every rupee released from central Government   reaches  to the intended beneficiary directly without any middlemen which has further led to the enhancement of Indian Economy . The once neglected poor section of the country has been  linked with the rising Indian Economy.This has been made possible with a mission-mode approach that involved both the government and the public.The Minister highlighted that JAM Trinity has driven the nation’s digital revolution and enhance transparency within the financial ecosystem. The government’s focus for the initiative is maximising value for every rupee spent, empowering the poor, and ensuring technology penetration among the masses has been achieved.The JAM Trinity has played a pivotal role in facilitating this progress, enabling more effective and inclusive financial transactions, particularly through Direct Benefit Transfers (DBT). This system has not only ensured subsidies and benefits reach the underprivileged directly but also reduced corruption and eliminated fake beneficiaries. The average deposits in the Jan Dhan Accounts as on 14.8.2024 is Rs 4352. The government has fought against poverty on all fronts and consequently,25 crore have come out of poverty in the last 10 years. Delhi alone has 65 lakh PM Jan Dhan Accounts with a total deposit of Rs 3114 crores along with 50 lakh beneficiaries of RuPAY Cards. 2,59,000 women have been benefited from the PM Ujjwala Scheme

    Minister of State emphasised that the success of PMJDY and the JAM trinity has brought greater financial inclusion, empowering citizens with access to banking services while promoting transparency and curbing corruption.PMJDY has not only transformed the financial landscape for millions of Indians but also paved the way for India to emerge as a global leader in digital financial inclusion. About 10 crore fake beneficiaries have been weeded out from the system  which has helped in prevent Rs 2.75 lakh crore from going into wrong hands.

    Shri Malhotra stated that India’s digital payment landscape has also seen exponential growth, with UPI transactions expanding rapidly. In FY 2023-24, UPI transactions reached ₹200 lakh crore, a 138% increase from 2017-18. This growth in digital payments has positioned India as a global leader in this domain, with UPI now operational in seven countries, further boosting financial inclusion and remittance flows. Through the continued expansion of digital payment solutions and initiatives like UPI, India is setting new benchmarks for economic empowerment and financial transparency and also mentioned that more than 40% of the global real-time payment transactions are happening in India.

    The Government’s focus on inclusive healthcare ensured that, India was just the fifth country to develop the COVID Vaccine and successfully executed  the world’s largest vaccine program in which 221 crore doses were administered to the people of the nation.

    Minister of State highlighted that Ayushman Bharat- PradhanMantri Jan Arogya Yojana (AB-PMJAY) which was launched on 23.09.2018 with an aim to provide health cover of Rs. 5 lakh per family per year for secondary and tertiary care hospitalisation. AB-PMJAY is presently implemented in 33 States/UTs across the country.

    In March 2024, 37 lakh families of ASHA, Anganwadi Worker and Anganwadi Helpers were also included in the scheme.

    Shri Malhotra mentioned that on 29.10.2024, the Government of India expanded the scheme to provide free treatment benefits of up to ₹5 lakh per year on a family basis to all senior citizens aged 70 years and above, irrespective of their socio-economic status. As on 30.11.2024, approximately 36 crore Ayushman cards have been created across the country and a total of  around 29,929 hospitals are empaneled under the scheme including 13,222 private hospitals, to ensure delivery of quality healthcare services to the beneficiaries. Further, a total of around8.39 crore hospital admissions worth aroundRs. 1.16 lakh crore have been authorized under the scheme.

    ****

    DSK

    (Release ID: 2086611) Visitor Counter : 32

    MIL OSI Asia Pacific News

  • MIL-OSI Europe: At a Glance – Plenary round-up – December 2024 – 20-12-2024

    Source: European Parliament

    The European Union’s external relations topped the agenda for the December 2024 plenary session, with several debates on statements by the High Representative for Foreign Affairs and Security Policy, and Vice-President of the European Commission, Kaja Kallas, attending the plenary for the first time in her new capacity. These included the toppling of the Syrian regime and its consequences; Russia’s disinformation activities and fraudulent justification of its war against Ukraine; the use of rape as a weapon of war (e.g. in the Democratic Republic of Congo and Sudan). The day after Kallas’s remarks on the crackdown on peaceful pro-European demonstrators in Georgia, Salome Zourabichvili, President of Georgia, addressed Members in a formal sitting. Other debates on Commission statements covered, inter alia: the situation in Mayotte following the recent devastating cyclone; a European innovation act; harassment and cyber-violence against female politicians in EU candidate and neighbouring countries; a shared vision for sustainable European tourism; promoting social dialogue and the right to strike; tackling abusive subcontracting; the need to ensure swift action and transparency on public-sector corruption allegations; urgent EU action to preserve nature and biodiversity; and the Commission’s plans to revise outstanding proposals on animal welfare in its 2025 work plan. Members also debated ahead of the European Council meeting of 19 December 2024 and set out their expectations ahead of the EU-Western Balkans Summit that took place the previous day. Parliament created two new standing committees, upgrading the former sub-committees on Public Health, and on Security and Defence; and set up two special committees: on the European Democracy Shield, and the Housing Crisis.

    MIL OSI Europe News

  • MIL-OSI Security: First Assistant United States Attorney Zachary T. Lee to Serve as Acting United States Attorney for the Western District of Virginia

    Source: Office of United States Attorneys

    ABINGDON, Va. – First Assistant United States Attorney Zachery T. Lee will serve as the Acting United States Attorney for the Western District of Virginia, effective December 21, 2024, at 12:00 a.m. He is assuming the office under the Federal Vacancies Reform Act, 5 U.S.C § 3345, upon the departure of United States Attorney Christopher R. Kavanaugh, who announced his resignation earlier this year.

    “For two decades, Zach Lee has served the Western District of Virginia with honor, distinction, and dedication as an Assistant United States Attorney, Criminal Chief, and most recently as First Assistant United States Attorney,” United States Attorney Kavanaugh said today. “There is nobody more qualified to serve in this role, and I look forward to watching the United States Attorney’s Office continue to thrive and serve the citizens of the Western District of Virginia under his leadership.”

    “In my role as the First Assistant United States Attorney, I’ve had the privilege to work side-by-side with Chris Kavanaugh on our district’s most pressing matters,” Mr. Lee said today. “We are sad to see Chris leave the Western District after more than a decade of service, but I promise to keep the men and women who work here focused on the priorities he’s put in place: Keeping our District safe, ensuring civil rights, reducing gun violence, and leading complex white collar investigations and prosecutions.”

    Mr. Lee, 48, has served the Department of Justice since joining the United States Attorney’s Office for the Western District of Virginia in 2005 as a Special Assistant United States Attorney, transitioning to an Assistant United States Attorney in 2007. During his tenure, Mr. Lee has prosecuted complex narcotics, public corruption, firearms, and other criminal matters. He also served in the district’s leadership team as Criminal Chief and First Assistant United States Attorney.

    Prior to his employment with the Department of Justice, Mr. Lee served as an Assistant Commonwealth’s Attorney for the City of Bristol, Virginia, and as a law clerk to the Honorable James P. Jones, United States District Judge for the Western District of Virginia.

    He earned his Juris Doctor from the University of Wyoming College of Law, Laramie, Wyoming, and a Bachelor of Arts from Washington and Lee University, Lexington, Virginia. 

    MIL Security OSI

  • MIL-OSI USA: US Department of Labor awards Florida $1.5M in funding to support jobs, training services in 21 counties affected by opioid crisis

    Source: US Department of Labor

    WASHINGTON – The U.S. Department of Labor today announced the award of $1.5 million in grant funding to Florida’s Department of Commerce to assist people affected by the health and economic effects of widespread opioid use, addiction and overdose.

    The opioid epidemic has significantly affected Florida’s workforce, with opioids involved in over 6,000 fatal overdoses in 2022, as well as contributing to absenteeism, increased healthcare costs, turnover, loss of productivity and shortages of treatment providers and facilities.

    Overseen by the department’s Employment and Training Administration, the National Health Emergency Dislocated Worker Grant will serve people in 21 counties across Florida by creating disaster-relief positions to address the shortage of health and counseling services available to individuals impacted by the opioid crisis.

    “The Employment and Training Administration is committed to ensuring Florida workers affected by the opioid crisis have access to assistance that will help their communities address the unique impacts of this complex public health crisis,” said Assistant Secretary for Employment and Training José Javier Rodríguez. “This Dislocated Worker Grant provides critical support to Florida by providing jobs to affected workers and training in the areas of addiction treatment, mental health and pain management.”

    Funds will also support employment and training services for workers experiencing unemployment and other workforce barriers resulting from the opioid crisis. Six workforce development boards will operate the project, serving eligible participants in Baker, Bay, Brevard, Clay, Duval, Flagler, Franklin, Gulf, Hillsborough, Lake, Manatee, Nassau, Orange, Osceola, Pinellas, Putnam, Sarasota, Seminole, St. Johns, Sumter and Volusia counties.

    In October 2017, the U.S. Department of Health and Human Services declared the opioid crisis a national public health emergency, enabling Florida to request this funding.

    Supported by the Workforce Innovation and Opportunity Act of 2014, Dislocated Worker Grants temporarily expand the service capacity of dislocated worker programs at the state and local levels by providing funding assistance in response to large, unexpected economic events that cause significant job losses.

    MIL OSI USA News

  • MIL-OSI Security: Former Doctor and Her Wife Sentenced for Fraud and Other Crimes

    Source: Federal Bureau of Investigation (FBI) State Crime News

    HUNTSVILLE, Ala. – A former family practice doctor in Huntsville was sentenced today for drug crimes, health care fraud, and COVID-19 disaster relief fraud, announced U.S. Attorney Prim F. Escalona, FBI Special Agent in Charge Carlton Peeples, Drug Enforcement Administration Special Agent in Charge Steven L. Hofer, and Special Agent in Charge Tamela Miles of the Department of Health and Human Service Office of the Inspector General Atlanta Region. The doctor’s wife, who owned the medical practice, was also sentenced.

    Judge Liles C. Burke sentenced Francene Aretha Gayle, 50, to 87 months in prison on four opioid prescribing charges, one count of health care fraud, and one count of wire fraud. Judge Burke sentenced Schara Monique Davis, 48, to 42 months in prison for one count of health care fraud and one count of wire fraud. Each defendant was also ordered to pay $2.2 million in restitution, forfeit $226,815, and pay a fine.

    According to the defendants’ plea agreements, between about 2014 and early 2020, Gayle was a doctor who operated a multi-clinic practice in Huntsville, Athens, and Killen. Davis owned the practice and served as business manager. In 2019, the Killen clinic shut down. In March 2020, the Alabama Medical Licensure Commission revoked Gayle’s license, and the other two clinics closed shortly after that.

    Gayle admitted that she had unlawfully distributed drugs, including oxycodone, hydrocodone, and methadone.

    Gayle and Davis both admitted to having conspired to commit health care fraud for several years by billing insurers for office visits under Gayle’s name even when she did not see the patients, was not in the same building, and sometimes was not in the same town. The defendants knew that the billing scheme was fraudulent. In 2015, Blue Cross Blue Shield of Alabama audited the practice and discovered that Gayle was absent, other staff were seeing patients, and yet all office visits were being billed under Gayle’s name. Blue Cross flagged the issue, and Gayle promised it would stop. Instead, the practice continued fraudulently billing insurers for office visits for the next four years. In total, between 2015 and 2020, Medicare, Medicaid, and Blue Cross paid more than $2.3 million for office visits billed under Gayle’s name.

    Gayle and Davis both also admitted to having conspired to commit wire fraud. In March 2020, based on concerns about her prescribing and billing practices, Gayle’s Alabama medical license was revoked.  Months later, Gayle and Davis applied for and obtained more than $450,000 in COVID-19 disaster relief funds through the Paycheck Protection Program (PPP) and Economic Injury Disaster Loan (EIDL) program. Those funds were designed to stabilize businesses struggling because of the pandemic. In their funding applications, Gayle and Davis certified that their medical practice needed the money because of economic uncertainty or injury caused by the pandemic. In reality, Gayle and Davis’s practice had closed, and they used COVID-19 funds they received on other things. 

    The FBI, DEA, and HHS-OIG investigated the case. The Medicaid Fraud Control Unit of the Alabama Attorney General’s Office provided exceptional investigative assistance after the Alabama Medicaid Agency’s Program Integrity Division initiated the case and referred it. Assistant U.S. Attorneys J.B. Ward and Ryan Rummage prosecuted the case. 

    MIL Security OSI

  • MIL-OSI USA: Recall of Jose Madrid Salsa Chipotle Con Queso

    Source: US Department of Health and Human Services – 3

    Summary

    Company Announcement Date:
    FDA Publish Date:
    Product Type:
    Food & Beverages
    Gravy/Sauces
    Allergens
    Reason for Announcement:

    Recall Reason Description

    Undeclared Yellow 5 and Yellow 6

    Company Name:
    Jose Madrid Salsa
    Brand Name:

    Brand Name(s)

    Jose Madrid

    Product Description:

    Product Description

    Chipotle Con Queso Salsa


    Company Announcement

    Jose Madrid Salsa is announcing a voluntary recall of our Chipotle Con Queso Salsa. The salsa is being recalled because it contains Yellow 5 and Yellow 6, which were not listed on the ingredient label. Individuals who are allergic or sensitive to Yellow 5 or Yellow 6 run the risk of minor to serious or life-threatening allergic reactions if they consume this product.

    The product was sold at the following events in NY and NC:
    Christmas in the Country event in Hamburg, NY November 7-10, 2024.
    Syracuse Holiday Shoppes event in Syracuse, NY November 8-10, 2024.
    Greensboro Holiday Market event in Greensboro, NC November 15-17, 2024.

    The recalled Jose Madrid Chipotle Con Queso Salsa, Net Wt. 13 oz., with UPC: 093662452935, is packaged in a Glass container. The lot codes, stamped on the top of the jar are:

    6012201
    102327

    6012201
    103027

    6012201
    111227

    No Illnesses have been reported to date.

    The problem was discovered during a routine inspection of the production facility by the Ohio Department of Agriculture acting on behalf of the FDA. Subsequent investigation indicates the problem was caused by a temporary breakdown in the company’s production and packaging processes.

    If you have one of these jars and you are allergic or sensitive to Yellow 5 and/or Yellow 6 you should not consume the product. Please contact us for additional information at 740-521-4304 or mike@josemadridsalsa.com, Monday through Friday 9am to 5pm.


    Company Contact Information


    Product Photos

    MIL OSI USA News

  • MIL-OSI USA: Medicare Advantage Provider Independent Health to Pay Up To $98M to Settle False Claims Act Suit

    Source: US State of California

    Independent Health Association and its affiliate, Independent Health Corporation (collectively, Independent Health) have agreed to pay up to $98 million to resolve allegations that they violated the False Claims Act by knowingly submitting or causing the submission of invalid diagnosis codes to Medicare for Medicare Advantage Plan enrollees to increase payments that Independent Health received from Medicare. Independent Health is headquartered in Buffalo, New York.

    Under Medicare Advantage, also known as the Medicare Part C program, Medicare beneficiaries have the option of enrolling in managed care insurance plans called Medicare Advantage Plans (MA Plans). MA Plans are paid a per-person amount to provide Medicare-covered benefits to beneficiaries who enroll in one of their plans. The Centers for Medicare and Medicaid Services (CMS), which oversees the Medicare program, adjusts the payments to MA Plans based on demographic information and the diagnoses of each plan beneficiary. The adjustments are commonly referred to as “risk scores.” In general, a beneficiary with diagnoses more expensive to treat will have a higher risk score, and CMS will make a larger risk-adjusted payment to the MA Plan for that beneficiary.

    Independent Health operates MA plans for beneficiaries living in western New York. As alleged by the United States, Independent Health created a wholly owned subsidiary, DxID LLC, to retrospectively search medical records and query physicians for information that would support additional diagnoses that could be used to generate higher risk scores, and DxID provided these services to Independent Health and other MA Plans. The United States filed a complaint alleging that, from 2011 through at least 2017, Independent Health, with the assistance of DxID and its founder and chief executive, Betsy Gaffney, knowingly submitted diagnoses to CMS that were not supported by the beneficiaries’ medical records in order to inflate Medicare’s payments to Independent Health.

    “The government expects those who participate in Medicare Advantage to provide accurate information to ensure that proper payments are made for the care received by enrolled beneficiaries,” said Deputy Assistant Attorney General Michael Granston of the Justice Department’s Civil Division. “Today’s result sends a clear message to the Medicare Advantage community that the United States will take appropriate action against those who knowingly submit inflated claims for reimbursement.”

    “To protect the integrity of Medicare and other federal health care programs, my office is committed to ensuring that each and every dollar meant for Medicare beneficiaries is spent appropriately and in accordance with the law,” said U.S. Attorney Trini E. Ross for the Western District of New York. “As this settlement makes clear, we will diligently pursue those who defraud government programs.”

    “Medicare Advantage Plans that attempt to game federal programs for profit must be held accountable through rigorous oversight and enforcement,” said Deputy Inspector General Christian J. Schrank of the Department of Health and Human Services Office of Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to root out fraud, waste and abuse in federal health care programs.”

    Under the terms of the settlement, Independent Health will make guaranteed payments of $34,500,000 and contingent payments of up to $63,500,000 on behalf it itself and DxID, which ceased operations in 2021. The settlement is based on Independent Health’s ability to pay. Gaffney will separately pay $2,000,000.

    In connection with the settlement, Independent Health entered into a five-year corporate integrity agreement (CIA) with HHS-OIG. The CIA requires, among other things, that Independent Health hire an Independent Review Organization to annually review a sample of Independent Health’s Medicare Advantage patients’ medical records and associated internal controls to help ensure appropriate risk adjustment payments.

    The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by Teresa Ross, a former employee of Group Health Cooperative, now Kaiser Foundation Health Plan of Washington (Kaiser). Under the qui tam provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. The Act permits the government to intervene in such lawsuits as it has done in this case. Ms. Ross will receive at least $8,212,500 of the settlement announced today. Ms. Ross also alleged that Kaiser employed DxID to identify additional diagnoses to be submitted to Medicare for risk adjustment, and the United States previously settled those claims with Kaiser.

    The United States’ intervention in this matter illustrates the government’s emphasis on combating health care fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to HHS, at 800-HHS-TIPS (800-447-8477).

    Attorneys Samson Asiyanbi and David Wiseman of the Civil Division’s Fraud Section and Assistant U.S. Attorney David Coriell and investigator Peggy McFarland for the Western District of New York handled the matter, with assistance from the HHS-OIG Buffalo Regional Office.

    The case is captioned United States ex rel. Ross v. Independent Health Association et al., No. 12-CV-0299(S) (WDNY).

    The claims resolved by the settlement are allegations only. There has been no determination of liability.

    View the settlement here.

    MIL OSI USA News

  • MIL-OSI Security: Medicare Advantage Provider Independent Health to Pay Up To $98M to Settle False Claims Act Suit

    Source: United States Attorneys General 7

    Independent Health Association and its affiliate, Independent Health Corporation (collectively, Independent Health) have agreed to pay up to $98 million to resolve allegations that they violated the False Claims Act by knowingly submitting or causing the submission of invalid diagnosis codes to Medicare for Medicare Advantage Plan enrollees to increase payments that Independent Health received from Medicare. Independent Health is headquartered in Buffalo, New York.

    Under Medicare Advantage, also known as the Medicare Part C program, Medicare beneficiaries have the option of enrolling in managed care insurance plans called Medicare Advantage Plans (MA Plans). MA Plans are paid a per-person amount to provide Medicare-covered benefits to beneficiaries who enroll in one of their plans. The Centers for Medicare and Medicaid Services (CMS), which oversees the Medicare program, adjusts the payments to MA Plans based on demographic information and the diagnoses of each plan beneficiary. The adjustments are commonly referred to as “risk scores.” In general, a beneficiary with diagnoses more expensive to treat will have a higher risk score, and CMS will make a larger risk-adjusted payment to the MA Plan for that beneficiary.

    Independent Health operates MA plans for beneficiaries living in western New York. As alleged by the United States, Independent Health created a wholly owned subsidiary, DxID LLC, to retrospectively search medical records and query physicians for information that would support additional diagnoses that could be used to generate higher risk scores, and DxID provided these services to Independent Health and other MA Plans. The United States filed a complaint alleging that, from 2011 through at least 2017, Independent Health, with the assistance of DxID and its founder and chief executive, Betsy Gaffney, knowingly submitted diagnoses to CMS that were not supported by the beneficiaries’ medical records in order to inflate Medicare’s payments to Independent Health.

    “The government expects those who participate in Medicare Advantage to provide accurate information to ensure that proper payments are made for the care received by enrolled beneficiaries,” said Deputy Assistant Attorney General Michael Granston of the Justice Department’s Civil Division. “Today’s result sends a clear message to the Medicare Advantage community that the United States will take appropriate action against those who knowingly submit inflated claims for reimbursement.”

    “To protect the integrity of Medicare and other federal health care programs, my office is committed to ensuring that each and every dollar meant for Medicare beneficiaries is spent appropriately and in accordance with the law,” said U.S. Attorney Trini E. Ross for the Western District of New York. “As this settlement makes clear, we will diligently pursue those who defraud government programs.”

    “Medicare Advantage Plans that attempt to game federal programs for profit must be held accountable through rigorous oversight and enforcement,” said Deputy Inspector General Christian J. Schrank of the Department of Health and Human Services Office of Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to root out fraud, waste and abuse in federal health care programs.”

    Under the terms of the settlement, Independent Health will make guaranteed payments of $34,500,000 and contingent payments of up to $63,500,000 on behalf it itself and DxID, which ceased operations in 2021. The settlement is based on Independent Health’s ability to pay. Gaffney will separately pay $2,000,000.

    In connection with the settlement, Independent Health entered into a five-year corporate integrity agreement (CIA) with HHS-OIG. The CIA requires, among other things, that Independent Health hire an Independent Review Organization to annually review a sample of Independent Health’s Medicare Advantage patients’ medical records and associated internal controls to help ensure appropriate risk adjustment payments.

    The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by Teresa Ross, a former employee of Group Health Cooperative, now Kaiser Foundation Health Plan of Washington (Kaiser). Under the qui tam provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. The Act permits the government to intervene in such lawsuits as it has done in this case. Ms. Ross will receive at least $8,212,500 of the settlement announced today. Ms. Ross also alleged that Kaiser employed DxID to identify additional diagnoses to be submitted to Medicare for risk adjustment, and the United States previously settled those claims with Kaiser.

    The United States’ intervention in this matter illustrates the government’s emphasis on combating health care fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to HHS, at 800-HHS-TIPS (800-447-8477).

    Attorneys Samson Asiyanbi and David Wiseman of the Civil Division’s Fraud Section and Assistant U.S. Attorney David Coriell and investigator Peggy McFarland for the Western District of New York handled the matter, with assistance from the HHS-OIG Buffalo Regional Office.

    The case is captioned United States ex rel. Ross v. Independent Health Association et al., No. 12-CV-0299(S) (WDNY).

    The claims resolved by the settlement are allegations only. There has been no determination of liability.

    View the settlement here.

    MIL Security OSI

  • MIL-OSI USA: Amendments to Executive Orders Relating to Certain Certificates and  Badges

    US Senate News:

    Source: The White House
         By the authority vested in me as President by the Constitution and the laws of the United States of America, and as Commander in Chief of the Armed Forces of the United States, it is hereby ordered as follows:
         Section 1.  Amendments to Executive Order 12793, as Amended.  Executive Order 12793 of March 20, 1992 (Continuing the Presidential Service Certificate and the Presidential Service Badge), as amended by Executive Order 13286 of February 28, 2003 (Amendment of Executive Orders, and Other Actions, in Connection With the Transfer of Certain Functions to the Secretary of Homeland Security), is further amended by:
         (a)  Amending section 1 to read as follows:
         “Section 1.  Presidential Service Certificate.  The Presidential Service Certificate (Certificate) is hereby continued, the design of which accompanies and is hereby made a part of this order.  The Certificate shall be awarded in the name of the President of the United States to members of the United States Uniformed Services who have been assigned to the White House Office; to military units and support facilities under the administration of the White House Military Office; or to other direct support positions within the Executive Office of the President (EOP).  The Certificate shall be awarded by the Secretary of the military department concerned, or, when the Coast Guard is not operating as a service in the Navy, by the Secretary of Homeland Security, and, in the case of members of the Commissioned Corps of the National Oceanic and Atmospheric Administration or the Commissioned Corps of the Public Health Service, by the Secretary of Commerce or the Secretary of Health and Human Services, respectively.  The Certificate shall not be issued to any member who is issued a Vice Presidential Certificate, or similar EOP Certificate, for the same period of service.  Such assignment must be for a period of at least 1 year, subsequent to January 21, 1989.”; and
         (b)  Amending section 2 to read as follows:
         “Sec. 2.  Presidential Service Badge.  The Presidential Service Badge (Badge) is hereby continued, the design of which accompanies and is hereby made a part of this order.  The Badge shall be awarded to those members of the United States Uniformed Services who have been granted the Certificate and shall be awarded in the same manner in which the Certificate has been given.  The Badge shall be worn as a part of the uniform of those individuals under such regulations as their respective Secretaries may severally prescribe.”.
         Sec. 2.  Amendments to Executive Order 11926, as Amended.  Executive Order 11926 of July 19, 1976 (The Vice Presidential Service Badge), as amended by Executive Order 13286 and by Executive Order 13373 of March 10, 2005 (Amendments to Executive Order 11926 Relating to the Vice Presidential Service Badge), is further amended by:
         (a)  Amending section 1 to read as follows:
         “Section 1.  There is established a Vice Presidential Service Badge to be awarded in the name of the Vice President of the United States of America to members of the United States Uniformed Services who have been assigned to duty in the Office of the Vice President for a period of at least 1 year subsequent to December 19, 1974, or who have been assigned to perform duties predominantly for the Vice President for a period of at least 1 year subsequent to January 20, 2001, in the implementation of Public Law 93-346, as amended, or in military units and support facilities to which section 1 of Executive Order 12793 of March 20, 1992, as amended, refers.”;
         (b)  Amending section 2 to read as follows:
         “Sec. 2.  The Vice Presidential Service Badge may be awarded, upon recommendation of the Vice President’s designee (with the concurrence of the Director of the White House Military Office in the case of personnel in military units or support facilities to which section 1 of Executive Order 12793, as amended, refers), by the Secretary of the military department concerned, or, when the Coast Guard is not operating as a service in the Navy, by the Secretary of Homeland Security, to military personnel of their respective services who have been assigned to duty in the Office of the Vice President and, in the case of members of the Commissioned Corps of the National Oceanic and Atmospheric Administration or the Commissioned Corps of the Public Health Service so assigned, by the Secretary of Commerce or the Secretary of Health and Human Services, respectively.”;
         (c)  Amending section 4 to read as follows:
         “Sec. 4.  Upon award, the Vice Presidential Service Badge may be worn as a part of the uniform of an individual both during and after their assignment to duty in the Office of the Vice President.”; and
         (d)  Amending section 6 to read as follows:
         “Sec. 6.  Notwithstanding the provisions of sections 1 and 2 of this order, any member of the United States Uniformed Services, who has been assigned to duty in the Office of the Vice President, or who has been assigned to perform duties predominantly for the Vice President, in the implementation of Public Law 93-346, as amended, or in military units and support facilities to which section 1 of Executive Order 12793, as amended, refers, is authorized, unless otherwise directed by the Director of the White House Military Office in the case of personnel in military units and support facilities to which section 1 of Executive Order 12793, as amended, refers, to wear the Vice Presidential Service Badge on their uniform commencing on the first day of such duty and thereafter while assigned to such duty.”.
         Sec. 3.  General Provisions.  (a)  Nothing in this order shall be construed to impair or otherwise affect:
    (i)   the authority granted by law to an executive department or agency, or the head thereof; or
    (ii)  the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.
         (b)  This order shall be implemented consistent with applicable law and subject to the availability of appropriations.
         (c)  This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.
                                 JOSEPH R. BIDEN JR.
    THE WHITE HOUSE,
        December 20, 2024.

    MIL OSI USA News

  • MIL-OSI Security: Two Arizonans Plead Guilty to Fraud Targeting AHCCCS

    Source: Office of United States Attorneys

    PHOENIX, Ariz. – CoEric Riley, 38, of Mesa, pleaded guilty on Tuesday to Healthcare Fraud. His co-defendant, Britney Gooch, 37, of Mesa, also pleaded guilty to Healthcare Fraud on November 21, 2024. Sentencing for Riley and Gooch is scheduled for February 21, 2025, before United States District Judge Krissa M. Lanham.

    Riley and Gooch admitted that they defrauded the Arizona Health Care Cost Containment System (AHCCCS), Arizona’s Medicaid agency, through their company New Horizons Behavioral Health, a behavioral health clinic in Mesa, Arizona. They further admitted that through New Horizons, they exploited AHCCCS’s American Indian Health Program (AIHP) by falsely billing for services that were not provided to AIHP patients. As a result of the fraudulent billing submissions, Riley and Gooch obtained approximately $3.3 million in illegitimate proceeds from AHCCCS.

    A conviction for Healthcare Fraud carries a maximum penalty of 10 years in prison and a fine of up to $250,000, or both.

    The Federal Bureau of Investigation – Phoenix Division conducted the investigation in this case. The United States Attorney’s Office, District of Arizona, Phoenix, is handling the prosecution.
     

    CASE NUMBER:           CR-24-01794-PHX-KML
    RELEASE NUMBER:    2024-179_Riley and Gooch

     

    # # #

    For more information on the U.S. Attorney’s Office, District of Arizona, visit http://www.justice.gov/usao/az/
    Follow the U.S. Attorney’s Office, District of Arizona, on X @USAO_AZ for the latest news.

    MIL Security OSI

  • MIL-OSI USA: Sixteen Cardiology Practices to Pay a Total of $17.7M to Resolve False Claims Act Allegations Concerning Inflated Medicare Reimbursements

    Source: US State Government of Utah

    Sixteen separate cardiology practices and associated physicians, located across 12 states, have agreed to pay amounts totaling $17,761,564 to resolve allegations that they each violated the False Claims Act by overbilling Medicare for diagnostic radiopharmaceuticals.

    Diagnostic radiopharmaceuticals are radioisotopes bound to biological molecules that target specific organs, tissues or cells within the human body and are used to diagnose and, in some cases, treat certain cancers and diseases. In 13 states and the District of Columbia, Medicare Part B reimburses healthcare providers for diagnostic radiopharmaceuticals based on the provider’s acquisition cost. In those jurisdictions, Medicare’s contractors have published guidance explaining the reimbursement methodology and providers’ obligation to accurately report their invoice costs for diagnostic radiopharmaceuticals. The government alleged that the settling cardiology practices regularly reported inflated acquisition costs to Medicare for these drugs. In each of the settlements, the conduct occurred for at least a year, and in some instances, the conduct extended over a period of more than 10 years.

    “The financial stability of federal healthcare programs depends upon providers complying with applicable billing rules,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “We are committed to ensuring that Medicare funds are expended appropriately and to pursuing those who knowingly fail to do so.”

    The settling medical practices and associated physicians have agreed to pay the following amounts:

    • Western Kentucky Heart & Lung Associates PSC and Mohammed Kazimuddin ($6,750,000)
    • Heart Clinic of Paris P.A. and Arjumand Hashmi ($2,600,000)
    • Scranton Cardiovascular Physician Services LLC ($2,369,111)
    • Shannon Clinic ($996,856)
    • Edward W. Leahey M.D. Professional Association and Edward Leahey ($894,679)
    • Metropolitan Cardiovascular Consultants LLC and Ayim Djamson ($846,888)
    • Cardiology Center of New Jersey LLC, Mario Criscito, Frank Iacovone, and Sameer Kaul ($740,000)
    • Clovis Cardiology Associates LLC and Mahamadu Fuseini ($600,000)
    • Family Medical Specialty Clinic PLLC, Melecio Abordo, and June Abadilla ($409,594)
    • James R. Higgins M.D. Inc. and James Higgins ($395,537)
    • TrustCare Health LLC ($279,407)
    • Taj Medical Inc. ($240,000)
    • White River Diagnostic Clinic PLC, Margaret Kuykendall, and Seth Barnes ($234,490)
    • Veinguard Heart & Vascular Center P.C. and Fareeha Khan ($195,000)
    • Boulder Medical Center PC ($160,000)
    • Wellspring Cardiac Care P.A. ($50,000).

    “Practices and providers who overcharge the government and fail to return overpayments compromise our healthcare programs,” said U.S. Attorney Matthew M. Graves for the District of Columbia. “When people see the wrong and report it, we have the tool we need to put a stop to this type of irresponsible conduct. So, I applaud the whistleblowers who came forward in this case.”

    “These practitioners overbilled the Medicare program by grossly exaggerating the acquisition costs of drugs used in diagnostic imaging of the heart,” said U.S. Attorney Michael A. Bennett for the Western District of Kentucky. “This office is committed to protecting our federal health care programs, and we will hold accountable anyone who seeks to exploit them.”

    “Medicare providers are required to be honest and accurate in the costs they report for reimbursement,” said Special Agent in Charge Maureen Dixon of the Department of Health and Human Services Office of the Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to investigate alleged false claims act violations and ensure the integrity of the Medicare program. ”

    The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by relators Jasjit Walia and Preet Randhawa in the District of Columbia and the Western District of Kentucky. Under those provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. The whistleblowers will receive a total of more than $2.7 million from the settlements announced today.

    The resolution obtained in this matter was the result of a coordinated effort between the Justice Department’s Civil Division, Commercial Litigation Branch, Fraud Section and the U.S. Attorneys’ Offices for the District of Columbia and Western District of Kentucky, with assistance from the HHS Office of Counsel to the Inspector General and Office of Investigations.

    The investigation and resolution of this matter illustrates the government’s emphasis on combating healthcare fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse and mismanagement, can be reported to HHS at 800-HHS-TIPS (800-447-8477).

    Trial Attorney James Nealon of the Justice Department’s Civil Division and Assistant U.S. Attorneys Ben Schecter, Matt Weyand, John Truong and Stephen DeGenaro for the District of Columbia handled the matter.

    The claims resolved by the settlements are allegations only. There has been no determination of liability.

    View the Heart Clinic of Paris settlement agreement here.

    View the Leahey settlement agreement here.

    View the Scranton settlement agreement here.

    View the Metropolitan settlement agreement here.

    View the Shannon Clinic settlement agreement here.

    View the Family Medical Specialty Clinic settlement agreement here.

    View the Taj Medical settlement agreement here.

    View the TrustCare settlement agreement here.

    View the Veinguard settlement agreement here.

    View the Wellspring settlement agreement here.

    View the White River settlement agreement here.

    View the WKHL settlement agreement here.

    View the Boulder Medical Center settlement agreement here.

    View the CCNJ settlement agreement here.

    View the Clovis settlement agreement here.

    View the Higgins settlement agreement here.

    MIL OSI USA News

  • MIL-OSI Security: Sixteen Cardiology Practices to Pay a Total of $17.7M to Resolve False Claims Act Allegations Concerning Inflated Medicare Reimbursements

    Source: United States Attorneys General 6

    Sixteen separate cardiology practices and associated physicians, located across 12 states, have agreed to pay amounts totaling $17,761,564 to resolve allegations that they each violated the False Claims Act by overbilling Medicare for diagnostic radiopharmaceuticals.

    Diagnostic radiopharmaceuticals are radioisotopes bound to biological molecules that target specific organs, tissues or cells within the human body and are used to diagnose and, in some cases, treat certain cancers and diseases. In 13 states and the District of Columbia, Medicare Part B reimburses healthcare providers for diagnostic radiopharmaceuticals based on the provider’s acquisition cost. In those jurisdictions, Medicare’s contractors have published guidance explaining the reimbursement methodology and providers’ obligation to accurately report their invoice costs for diagnostic radiopharmaceuticals. The government alleged that the settling cardiology practices regularly reported inflated acquisition costs to Medicare for these drugs. In each of the settlements, the conduct occurred for at least a year, and in some instances, the conduct extended over a period of more than 10 years.

    “The financial stability of federal healthcare programs depends upon providers complying with applicable billing rules,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “We are committed to ensuring that Medicare funds are expended appropriately and to pursuing those who knowingly fail to do so.”

    The settling medical practices and associated physicians have agreed to pay the following amounts:

    • Western Kentucky Heart & Lung Associates PSC and Mohammed Kazimuddin ($6,750,000)
    • Heart Clinic of Paris P.A. and Arjumand Hashmi ($2,600,000)
    • Scranton Cardiovascular Physician Services LLC ($2,369,111)
    • Shannon Clinic ($996,856)
    • Edward W. Leahey M.D. Professional Association and Edward Leahey ($894,679)
    • Metropolitan Cardiovascular Consultants LLC and Ayim Djamson ($846,888)
    • Cardiology Center of New Jersey LLC, Mario Criscito, Frank Iacovone, and Sameer Kaul ($740,000)
    • Clovis Cardiology Associates LLC and Mahamadu Fuseini ($600,000)
    • Family Medical Specialty Clinic PLLC, Melecio Abordo, and June Abadilla ($409,594)
    • James R. Higgins M.D. Inc. and James Higgins ($395,537)
    • TrustCare Health LLC ($279,407)
    • Taj Medical Inc. ($240,000)
    • White River Diagnostic Clinic PLC, Margaret Kuykendall, and Seth Barnes ($234,490)
    • Veinguard Heart & Vascular Center P.C. and Fareeha Khan ($195,000)
    • Boulder Medical Center PC ($160,000)
    • Wellspring Cardiac Care P.A. ($50,000).

    “Practices and providers who overcharge the government and fail to return overpayments compromise our healthcare programs,” said U.S. Attorney Matthew M. Graves for the District of Columbia. “When people see the wrong and report it, we have the tool we need to put a stop to this type of irresponsible conduct. So, I applaud the whistleblowers who came forward in this case.”

    “These practitioners overbilled the Medicare program by grossly exaggerating the acquisition costs of drugs used in diagnostic imaging of the heart,” said U.S. Attorney Michael A. Bennett for the Western District of Kentucky. “This office is committed to protecting our federal health care programs, and we will hold accountable anyone who seeks to exploit them.”

    “Medicare providers are required to be honest and accurate in the costs they report for reimbursement,” said Special Agent in Charge Maureen Dixon of the Department of Health and Human Services Office of the Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to investigate alleged false claims act violations and ensure the integrity of the Medicare program. ”

    The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by relators Jasjit Walia and Preet Randhawa in the District of Columbia and the Western District of Kentucky. Under those provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. The whistleblowers will receive a total of more than $2.7 million from the settlements announced today.

    The resolution obtained in this matter was the result of a coordinated effort between the Justice Department’s Civil Division, Commercial Litigation Branch, Fraud Section and the U.S. Attorneys’ Offices for the District of Columbia and Western District of Kentucky, with assistance from the HHS Office of Counsel to the Inspector General and Office of Investigations.

    The investigation and resolution of this matter illustrates the government’s emphasis on combating healthcare fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse and mismanagement, can be reported to HHS at 800-HHS-TIPS (800-447-8477).

    Trial Attorney James Nealon of the Justice Department’s Civil Division and Assistant U.S. Attorneys Ben Schecter, Matt Weyand, John Truong and Stephen DeGenaro for the District of Columbia handled the matter.

    The claims resolved by the settlements are allegations only. There has been no determination of liability.

    View the Heart Clinic of Paris settlement agreement here.

    View the Leahey settlement agreement here.

    View the Scranton settlement agreement here.

    View the Metropolitan settlement agreement here.

    View the Shannon Clinic settlement agreement here.

    View the Family Medical Specialty Clinic settlement agreement here.

    View the Taj Medical settlement agreement here.

    View the TrustCare settlement agreement here.

    View the Veinguard settlement agreement here.

    View the Wellspring settlement agreement here.

    View the White River settlement agreement here.

    View the WKHL settlement agreement here.

    View the Boulder Medical Center settlement agreement here.

    View the CCNJ settlement agreement here.

    View the Clovis settlement agreement here.

    View the Higgins settlement agreement here.

    MIL Security OSI

  • MIL-OSI USA: FDA Approves First Medication for Obstructive Sleep Apnea

    Source: US Department of Health and Human Services – 3

    For Immediate Release:

    Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.

    “Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research. “This is a major step forward for patients with obstructive sleep apnea.”

    OSA occurs when a person’s upper airway becomes blocked, causing pauses in breathing during sleep. While OSA can affect anyone, it is more common in people who have overweight or obesity. Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. By reducing body weight, studies show that Zepbound also improves OSA.

    Zepbound’s approval for moderate to severe OSA in adults with obesity is based on two randomized, double-blind, placebo-controlled studies of 469 adults without type 2 diabetes. One study enrolled participants using positive airway pressure (PAP), the standard of care for moderate to severe OSA, and one study enrolled participants unable or unwilling to use PAP. In both studies, participants randomly received either 10 or 15 milligrams of Zepbound or placebo once weekly for 52 weeks. The primary measure of efficacy was the change from baseline in the apnea hypopnea index (AHI), a measurement of how many times a person stops breathing (apnea) or breathes shallowly (hypopnea) per hour during sleep, at week 52. After 52 weeks of treatment in both studies, participants who received Zepbound experienced a statistically significant and clinically meaningful reduction in events of apnea or hypopnea as measured by AHI compared with placebo, and greater proportions of participants treated with Zepbound achieved remission or mild OSA with resolution of symptoms compared to placebo. Participants treated with Zepbound had a significant decrease in body weight compared with placebo at 52 weeks. The improvement in AHI in participants with OSA is likely related to body weight reduction with Zepbound.  

    Zepbound can cause side effects such as nausea, diarrhea, vomiting, constipation, abdominal (stomach) discomfort and pain, injection site reactions, fatigue, hypersensitivity (allergic) reactions (typically fever and rash), burping, hair loss and gastroesophageal reflux disease.

    Zepbound causes thyroid C-cell tumors in rats. It is unknown whether Zepbound causes such tumors, including medullary thyroid cancer, in humans. Zepbound should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.

    Zepbound should not be used in patients with a history of severe allergic reaction to tirzepatide (its active ingredient) or to any of its other ingredients. Patients should stop Zepbound immediately and seek medical help if a severe allergic reaction is suspected.

    Zepbound also contains warnings for inflammation of the pancreas (pancreatitis), gallbladder problems, hypoglycemia (blood sugar that is too low), acute kidney injury, diabetic retinopathy (damage to the eye’s retina) in patients with type 2 diabetes mellitus, suicidal behavior or thinking, and pulmonary aspiration during general anesthesia or deep sedation. Patients should discuss with their health care provider if they have symptoms of pancreatitis or gallstones. If Zepbound is used with insulin or a medication that causes insulin secretion, patients should speak to their health care provider about potentially lowering the dose of these other medicines to reduce the risk of hypoglycemia. Health care providers should monitor patients with kidney disease, diabetic retinopathy and depression or suicidal behaviors or thoughts. Patients taking Zepbound should inform healthcare providers of any planned surgeries of procedures.

    Zepbound received Fast Track, Priority Review and Breakthrough Therapy designations for this indication.

    The FDA granted the approval to Eli Lilly and Co.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Consumer:
    888-INFO-FDA

    MIL OSI USA News

  • MIL-OSI USA: Chinese National Indicted in El Paso, Texas, and Arrested in Las Vegas for Alleged Conspiracy to Sell Equipment Used to Manufacture Counterfeit Pills

    Source: US State Government of Utah

    A federal grand jury in the Western District of Texas charged a Chinese national with two counts related to alleged distribution of pill press equipment that can be used by criminals to manufacture illegal drugs laced with fentanyl.

    Department of Homeland Security agents arrested the defendant, Xaiofei Chen, at a trade show in Las Vegas on Oct. 29. According to the criminal complaint supporting her arrest warrant, Chen sold pill press machines that can be used with molds, stamps or dies mimicking commonly prescribed controlled substances to produce counterfeit pills that appear indistinguishable from legitimate pharmaceutical drugs. Specifically, the criminal complaint alleges that Chen worked for a Chinese-based company that sold die molds and equipment, and that Chen sold pill press equipment and counterfeit die molds to buyers in the United States. The complaint further alleges that Chen avoided Drug Enforcement Administration (DEA) disclosure requirements by dismantling equipment and shipping parts in separate packages into the United States. This equipment allegedly included counterfeit dies, including M30 dies meant to mimic a common prescription drug but which are regularly used to make fake opioid pills. The complaint alleges that the packages that Chen sent also were mislabeled to conceal the illegal equipment that they contained.

    The Controlled Substances Act prohibits the sale of pill press equipment and counterfeit die molds to individuals who intend to use these machines unlawfully and requires reporting of certain equipment sales. Counterfeit pills made on such equipment can be laced with fentanyl and other dangerous drugs. According to the Centers for Disease Control and Prevention (CDC), fentanyl is a highly addictive synthetic opioid that is 50 times more potent than heroin and 100 times more potent than morphine. Fentanyl and related substances have devastated communities across the United States and fuel the ongoing drug overdose epidemic, which the CDC recently estimated killed approximately 107,000 Americans in 2023. Fentanyl overdose is the leading cause of death for Americans ages 18 to 49. In recent years, more than half of counterfeit pills tested have been found to have a potentially lethal dose of fentanyl.

    “The fentanyl epidemic has taken hundreds of thousands of American lives, and this case reflects the department’s unwavering commitment to prosecuting every level of the deadly fentanyl supply chain,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “The department will continue to protect Americans by prosecuting those involved in the unlawful sale of parts and equipment that can be used to manufacture counterfeit pills.”

    “The defendant allegedly sold equipment that can be used to make dangerous opioid pills harmful to American families,” said Executive Associate Director Katrina W. Berger of Homeland Security Investigations (HSI). “HSI is proud to work with our law enforcement partners to prevent the distribution of equipment commonly used in the manufacture of these destructive drugs.”

    A federal court in Nevada ordered Chen, a foreign national, detained pending her trial in El Paso where the indictment was returned on Nov. 20. The indictment charges Chen with one count of conspiracy to distribute and import a tableting machine used to manufacture a controlled substance and one count of conspiracy to distribute dies designed to imprint and reproduce the trademark, trade name and other identifying mark and imprint of another. If convicted, Chen faces a maximum penalty of four years in prison and a $250,000 fine. A federal district court judge would determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.

    HSI and Customs and Border Protection are investigating the case.

    Trial Attorneys Edward E. Emokpae, Scott B. Dahlquist and Kaitlin Sahni of the Civil Division’s Consumer Protection Branch and Assistant U.S. Attorneys Laura Franco Gregory and Donna S. Miller for the Western District of Texas are prosecuting the case. Attorneys Colin Trundle and Sarah Williams of the Consumer Protection Branch also provided valuable assistance.

    An indictment or complaint is merely an allegation. All defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.

    MIL OSI USA News

  • MIL-OSI Security: More Than a Dozen Cardiology Practices Will Pay Over $17.7 Million to Resolve False Claims Act Allegations Concerning Inflated Medicare Reimbursements

    Source: Office of United States Attorneys

                WASHINGTON – The U.S. Attorney’s Office announced today the resolution of False Claims Act violations against 16 separate cardiology practices and associated physicians, located across 12 states, and their agreement to pay a total of $17,761,564 to resolve allegations that they violated the False Claims Act by overbilling Medicare for diagnostic radiopharmaceuticals. The U.S. Attorney’s Office for the District of Columbia was involved in 14 of these settlements, resulting in a total of $10,601,970.97. The remaining amount was captured by the U.S. Attorney’s Office for the Western District of Kentucky. The Department of Justice also announced these settlements.

              Diagnostic radiopharmaceuticals are radioisotopes bound to biological molecules that target specific organs, tissues or cells within the human body and are used to diagnose and in some cases, treat certain cancers and diseases. In 13 states and the District of Columbia, Medicare Part B reimburses healthcare providers for diagnostic radiopharmaceuticals based on the provider’s acquisition cost. In those jurisdictions, Medicare’s contractors have published guidance explaining the reimbursement methodology and providers’ obligation to accurately report their invoice cost for diagnostic radiopharmaceuticals. The government alleged that the settling cardiology practices regularly reported inflated acquisition costs to Medicare for these drugs. In each of the settlements, the conduct occurred for at least a year, and in some instances, the conduct extended over a period of more than 10 years.

              “Practices and providers who overcharge the government and fail to return overpayments compromise our healthcare programs,” said U.S. Attorney Graves. “When people see the wrong and report it, we have the tool we need to put a stop to this type of irresponsible conduct. So I applaud the whistleblowers who came forward in this case.”

              “The integrity of federal healthcare programs depends upon compliance with billing rules that are used to determine reimbursement,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “We are committed to ensuring that Medicare funds are expended appropriately.”

              The settling medical practices and associated physicians have agreed to pay the following amounts:

    •           Heart Clinic of Paris, P.A. and Arjumand Hashmi ($2.6m)

    •           Scranton Cardiovascular Physician Services, LLC ($2,369,111)

    •           Shannon Clinic ($996,856)

    •           Edward W. Leahey M.D. Professional Association and Edward Leahey ($894,679)

    •           Metropolitan Cardiovascular Consultants, LLC and Ayim Djamson ($846,888)

    •           Cardiology Center of New Jersey, LLC, Mario Criscito, Frank Iacovone, and Sameer Kaul ($740,000)

    •           Clovis Cardiology Associates LLC and Mahamadu Fuseini ($600,000)

    •           James R. Higgins M.D., Inc. and James Higgins ($395,537)

    •           TrustCare Health, LLC ($279,407)

    •           Taj Medical, Inc. ($240,000)

    •           White River Diagnostic Clinic, PLC, Margaret Kuykendall, and Seth Barnes ($234,490)

    •           Boulder Medical Center, PC ($160,000)

    •           (USAO-WDKY) Western Kentucky Heart & Lung Associates PSC and Mohammed Kazimuddin ($6,750,000)

    •           (USAO-WDKY) Family Medical Specialty Clinic, PLLC, Melecio Abordo, and June Abadilla ($409,594)

              “These practitioners overbilled the Medicare program by grossly exaggerating the acquisition costs of drugs used in diagnostic imaging of the heart,” said Michael A. Bennett, United States Attorney for the Western District of Kentucky. “This Office is committed to protecting our federal health care programs, and we will hold accountable anyone who seeks to exploit them.”

              “Medicare providers are required to be honest and accurate in the costs they report for reimbursement,” said Special Agent in Charge Maureen Dixon, for the Department of Health and Human Services Office of the Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to investigate alleged false claims act violations and ensure the integrity of the Medicare program.”

              The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by relators Jasjit Walia and Preet Randhawa in the District of Columbia and the Western District of Kentucky.  Under those provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery.  The whistleblowers will receive a total of approximately $2.2 million from the settlements announced today.

              The resolution obtained in this matter was the result of a coordinated effort between the Justice Department’s Civil Division, Commercial Litigation Branch, Fraud Section and the United States Attorney’s Offices for the District of Columbia and Western District of Kentucky, with assistance from the Department of Health and Human Services, Office of Counsel to the Inspector General and Office of Investigations.

              The investigation and resolution of this matter illustrates the government’s emphasis on combating healthcare fraud.  One of the most powerful tools in this effort is the False Claims Act.  Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

              The matter was handled by Trial Attorney James Nealon and Assistant U.S. Attorneys Ben Schecter and Matt Weyand from Western District of Kentucky, and Stephen DeGenaro and John C. Truong from the District of Columbia.

    The claims resolved by the settlement are allegations only and there has been no determination of liability.

    MIL Security OSI

  • MIL-OSI Security: Chinese National Indicted in El Paso, Texas, and Arrested in Las Vegas for Alleged Conspiracy to Sell Equipment Used to Manufacture Counterfeit Pills

    Source: United States Attorneys General

    A federal grand jury in the Western District of Texas charged a Chinese national with two counts related to alleged distribution of pill press equipment that can be used by criminals to manufacture illegal drugs laced with fentanyl.

    Department of Homeland Security agents arrested the defendant, Xaiofei Chen, at a trade show in Las Vegas on Oct. 29. According to the criminal complaint supporting her arrest warrant, Chen sold pill press machines that can be used with molds, stamps or dies mimicking commonly prescribed controlled substances to produce counterfeit pills that appear indistinguishable from legitimate pharmaceutical drugs. Specifically, the criminal complaint alleges that Chen worked for a Chinese-based company that sold die molds and equipment, and that Chen sold pill press equipment and counterfeit die molds to buyers in the United States. The complaint further alleges that Chen avoided Drug Enforcement Administration (DEA) disclosure requirements by dismantling equipment and shipping parts in separate packages into the United States. This equipment allegedly included counterfeit dies, including M30 dies meant to mimic a common prescription drug but which are regularly used to make fake opioid pills. The complaint alleges that the packages that Chen sent also were mislabeled to conceal the illegal equipment that they contained.

    The Controlled Substances Act prohibits the sale of pill press equipment and counterfeit die molds to individuals who intend to use these machines unlawfully and requires reporting of certain equipment sales. Counterfeit pills made on such equipment can be laced with fentanyl and other dangerous drugs. According to the Centers for Disease Control and Prevention (CDC), fentanyl is a highly addictive synthetic opioid that is 50 times more potent than heroin and 100 times more potent than morphine. Fentanyl and related substances have devastated communities across the United States and fuel the ongoing drug overdose epidemic, which the CDC recently estimated killed approximately 107,000 Americans in 2023. Fentanyl overdose is the leading cause of death for Americans ages 18 to 49. In recent years, more than half of counterfeit pills tested have been found to have a potentially lethal dose of fentanyl.

    “The fentanyl epidemic has taken hundreds of thousands of American lives, and this case reflects the department’s unwavering commitment to prosecuting every level of the deadly fentanyl supply chain,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “The department will continue to protect Americans by prosecuting those involved in the unlawful sale of parts and equipment that can be used to manufacture counterfeit pills.”

    “The defendant allegedly sold equipment that can be used to make dangerous opioid pills harmful to American families,” said Executive Associate Director Katrina W. Berger of Homeland Security Investigations (HSI). “HSI is proud to work with our law enforcement partners to prevent the distribution of equipment commonly used in the manufacture of these destructive drugs.”

    A federal court in Nevada ordered Chen, a foreign national, detained pending her trial in El Paso where the indictment was returned on Nov. 20. The indictment charges Chen with one count of conspiracy to distribute and import a tableting machine used to manufacture a controlled substance and one count of conspiracy to distribute dies designed to imprint and reproduce the trademark, trade name and other identifying mark and imprint of another. If convicted, Chen faces a maximum penalty of four years in prison and a $250,000 fine. A federal district court judge would determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.

    HSI and Customs and Border Protection are investigating the case.

    Trial Attorneys Edward E. Emokpae, Scott B. Dahlquist and Kaitlin Sahni of the Civil Division’s Consumer Protection Branch and Assistant U.S. Attorneys Laura Franco Gregory and Donna S. Miller for the Western District of Texas are prosecuting the case. Attorneys Colin Trundle and Sarah Williams of the Consumer Protection Branch also provided valuable assistance.

    An indictment or complaint is merely an allegation. All defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.

    MIL Security OSI

  • MIL-OSI USA: Endo USA, Inc. Issues Voluntary, Nationwide Recall of Adrenalin® Chloride Solution (EPINEPHrine Nasal Solution, USP) Due to the Potential for Administration Errors

    Source: US Department of Health and Human Services – 3

    Summary

    Company Announcement Date:
    FDA Publish Date:
    Product Type:
    Drugs
    Reason for Announcement:

    Recall Reason Description

    Product is an unapproved drug.

    Company Name:
    Endo, Inc.
    Brand Name:

    Brand Name(s)

    Par Pharmaceutical

    Product Description:

    Product Description

    Adrenalin® Chloride Solution (EPINEPHrine nasal solution, USP)


    Company Announcement

    MALVERN, PA, December 20, 2024 – Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling all lots within expiry of Adrenalin® Chloride Solution (EPINEPHrine nasal solution, USP) 30mg/30mL (1mg/mL) 30 mL vials, to the consumer level. This product, which pre-dates the 1938 Federal Food, Drug & Cosmetic Act, was never submitted for approval by the FDA, and as such, is an unapproved drug for which safety and efficacy have not been established and, therefore, subject to recall. In addition, FDA has determined the product to be misbranded with a misleading label similar in appearance to the FDA-approved drug product Adrenalin® (epinephrine injection, USP) (1mg/mL) 30mL vial, also produced by Endo USA, Inc.

    Both products are distributed to hospitals and healthcare systems for use by healthcare professionals. The similarity in labeling makes it difficult to distinguish between the non-sterile topical and sterile injectable product which can lead to potential administration errors. This recall does not include the approved Adrenalin® (epinephrine injection, USP) (1mg/mL) 30mL vial.

    Risk Statement: Intravenous administration of the unapproved non-sterile topical Adrenalin® Chloride Solution (EPINEPHrine nasal solution, USP), instead of the approved sterile Adrenalin® (epinephrine injection, USP) (1mg/mL) 30mL vial for injection, would result in non-fatal serious and/or severe, health outcomes related to delayed or inadequate treatment of the underlying condition (anaphylaxis, hemodynamic instability, hypotension) or infection due to intravenous administration of a non-sterile product. In addition, there is a high probability that intravenous administration of the nasal product will result in patients receiving the wrong dose of epinephrine in emergency situations for serious, life-threatening conditions such as the treatment of anaphylaxis, blood pressure support, and cardiac arrest. If these events are not treated with the correct dose of epinephrine, patients may be at risk for death.

    Endo has not received reports of adverse events in the last five years.

    Adrenalin® Chloride Solution (EPINEPHrine nasal solution, USP) is a vasoconstrictor for topical application. The 30 mL vial is distributed in individually packed cartons under NDC #42023-103-01 with the language “Nasal Solution USP” and “For Topical Application” on the package. The product lots being recalled were distributed nationwide to wholesale distributors from October 10, 2023, through December 11, 2024.

    This recall impacts the following product lots:

    Product 

    NDC 

    Lot # 

    Date of Expiry 

    Adrenalin® Chloride Solution (EPINEPHrine
    Nasal Solution, USP) for topical application
    30mg/30mL (1mg/mL)

    42023-103-01

    82809

    03/2026

    79637

    11/2025

    77776

    07/2025

    74716

    05/2025

    71835

    01/2025

    72916

    01/2025

    Package Identification: See example of vial label from the affected lots attached to this press release.

    Endo is providing written notification to all direct customer accounts that have received the affected product lots and is arranging for return of all existing inventory through Inmar, Inc. Wholesale distributors that have the product lots being recalled should immediately discontinue use and stop distribution immediately.

    Questions regarding this recall can be directed to Inmar, Inc. at 1-877-560-8453 Monday through Friday between the hours of 9 a.m. and 5 p.m. EST or by email at rxrecalls@inmar.com. For medical or technical product information or to report a product complaint or adverse event please call 1-800-828-9393.

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    • Complete and submit the report Online
    • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements including but not limited to any statements related to product recalls, mislabeling, misbranding, safety concerns, administration errors, adverse events, FDA or other regulatory actions and any other statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “guidance,” “future,” “potential” or similar expressions are forward-looking statements. Because these statements reflect Endo’s current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of risks, uncertainties and factors, including risks and uncertainties related to the recall and any future recalls, potential adverse events and any regulatory actions by the FDA. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo’s public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading “Risk Factors” in Endo’s most recent Form 10-Q and in Endo’s final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with its Form S-1/A.

    Customers:      Media:
    Inmar, Inc.      Linda Huss
    1-877-560-8453      media.relations@endo.com


    Company Contact Information

    Consumers:
    Inmar, Inc.
    1-877-560-8453

    MIL OSI USA News

  • MIL-OSI USA: Legionella Bacteria Detected in Baltimore City Circuit and District Courts

    Source: US State of Maryland

    FOR IMMEDIATE RELEASE
    December 20, 2024

    Government Relations and Public Affairs
    187 Harry S. Truman Parkway
    Annapolis, Maryland 21401

    Legionella Bacteria Detected in Baltimore City Circuit and District Courts
    Cummings, Mitchell, and Civil Courthouses Closed Monday and Tuesday

    Circuit Courts:
    The Clerk of the Court at the Circuit Court of Baltimore City informed the Maryland Judiciary Friday morning, December 20, 2024, that a member of his staff is suspected of having been exposed to Legionella Pneumonia. The Maryland Judiciary leadership, Baltimore City courts leadership, and Baltimore City leadership met and were informed by City of Baltimore Mayor Brandon M. Scott that the Mitchell and Cummings circuit courthouses tested positive for Legionella bacteria.

    The Mitchell and Cummings courthouses were closed this afternoon to implement safety protocols and begin remediation steps. Following recommendations from health officials, Administrative Judge Audrey J.S. Carrion issued an Administrative Order to close the Michell and Cummings courthouses on Monday, December 23, and Tuesday, December 24, for remediation by the City of Baltimore Department of General Services. Both courthouses are scheduled to reopen on Thursday, December 26, 2024, at 8 a.m. Emergency matters will be heard on Monday, December 23, and Tuesday, December 24, at the Baltimore City Juvenile Justice Center, 300 N. Gay Street, Baltimore.

    The Baltimore City circuit courthouses will be providing signage in all public bathrooms. Hand sanitizer and bottled water will be available for employees and visitors.

    District Courts: 
    The Maryland Judiciary was informed on December 6, 2024, that the Wabash and Patapsco district courthouses had tested positive for legionella bacteria. Since that time, the water supply systems at both courthouses were flushed and treated and additional tests were performed. Drinking fountains were blocked, signage notifying employees and visitors was posted in all bathrooms, and hand sanitizer and bottled water were made available for both employees and the public.

    In addition, tests were performed at the Civil building on December 9, 2024, and the North Avenue courthouse on December 17, 2024. We were notified of positive test results for the Civil courthouse today, December 20, 2024. The Civil courthouse will be closed Monday, December 23, and Tuesday, December 24, for remediation by the City of Baltimore Department of General Services. Both courthouses are scheduled to reopen on Thursday, December 26, 2024, at 8 a.m. All emergency housing matters typically handled at the Civil courthouse will be moved to the Wabash District Court on Monday, December 23, 2024, and Tuesday, December 24, 2024. Wabash, Patapsco, and North Avenue courthouses will continue normal operations.

    The Maryland Judiciary was informed late yesterday, December 19, 2024, that the results from the testing at both Wabash and Patapsco continued to show positive results of the legionella bacteria. The Maryland Department of General Services has confirmed that an updated remedial plan has been put in place at these courthouses. The Maryland Department of General Services, after consultation with Maryland Department of Health, has provided health guidance to the District Court of Maryland regarding Legionella bacteria. The same guidance applies to the Circuit Court for Baltimore City.

    Based on the information provided by the Maryland Department of General Services and the Maryland Department of Health, the precautions that have been taken at the Baltimore City courthouses are sufficient to safely remain open.

    Please contact the Maryland Judiciary, Government Relations and Public Affairs Division, at [email protected] or 410-260-1488, for questions.

    ###

    MIL OSI USA News

  • MIL-OSI USA: Lidl Recalls Taste of Deutschland Buttered Vegetables Due to Undeclared Milk Allergens

    Source: US Department of Health and Human Services – 3

    Summary

    Company Announcement Date:
    FDA Publish Date:
    Product Type:
    Food & Beverages
    Vegetable Products
    Allergens
    Reason for Announcement:

    Recall Reason Description

    Undeclared milk

    Company Name:
    Lidl US
    Brand Name:

    Brand Name(s)

    Taste of Deutschland

    Product Description:

    Product Description

    Frozen Buttered Vegetables, Carrots, Peas, Cauliflower, & Corn


    Company Announcement

    ARLINGTON, VA – DECEMBER 20, 2024 – Lidl US is recalling all lots of their Taste of Deutschland Buttered Vegetables 10.5 oz box UPC 4 056489 122876 due to undeclared milk allergen. The recall was issued due to undeclared milk in the products. People who have allergies to milk run the risk of serious or life-threatening allergic reactions if they consume these products.

    Lidl US has received no reports or complaints of illness related to this product to date.

    The recall was initiated after it was discovered by the FDA during an inspection that the labels did not list the allergen milk in the ingredient statement.

    The products were distributed between 10/21/2023 – 12/19/2024. The product was distributed to all Lidl US store locations in Delaware, District of Columbia, Georgia, Maryland, New Jersey, New York, North Carolina, Pennsylvania, South Carolina, and Virginia.

    If customers have purchased this product, they should not consume it and immediately return it to their nearest Lidl store for a full refund (a receipt is not required for return). Customers who have questions about this voluntary recall should call the Lidl US Customer Care Hotline at (844)-747-5435 8 am-8 pm ET, Monday-Saturday.

    The health and safety of our customers is our top priority. Lidl US regrets any inconvenience related to this voluntary recall. Our Quality Assurance Department is constantly working to ensure that all products on our shelves meet the high-quality standards that we would expect when feeding our own families. We are grateful for all our Lidl US customers who choose to shop with us every day.


    Company Contact Information

    Consumers:
    Lidl US Customer Care Hotline
    (844)-747-5435

    Product Photos

    MIL OSI USA News

  • MIL-OSI Asia-Pac: Crowd safety management measures and special traffic arrangements for Lunar New Year fireworks display

    Source: Hong Kong Government special administrative region

         Police will implement crowd safety management measures and special traffic arrangements on both sides of Victoria Harbour on January 30 (Thursday) to facilitate the public to watch the Lunar New Year fireworks display.
     
    Kowloon
    ——-
     
    Crowd safety management measures in Tsim Sha Tsui
    ————————————————-
     
         Police will implement crowd safety management measures in Yau Tsim District and Hung Hom Waterfront Promenade, including pedestrianising roads at Tsim Sha Tsui and Hung Hom Waterfront Promenade in phases.
     
         Depending on the prevailing crowd situation, Police will implement safety measures within the pedestrianised area including the closure of pedestrian subways and putting up barriers. One-way flow will be applied on overcrowded footbridges and in the vicinity of the waterfront promenade. If necessary, restrictions on access to MTR stations will be put into force by the MTR Corporation.
     
         The Hong Kong Cultural Centre, the vicinity of the Clock Tower, and the Avenue of Stars are known to be popular gathering and vantage points. If these areas are saturated, the crowd will be diverted to other areas.
     
         At present, there are some construction works at West Kowloon Cultural District. The contractors have erected hoardings and barriers to seal off the area concerned with relevant notices displayed. Members of the public are urged not to enter these construction sites nor climb or lean against the barriers.
     
         Members of the public should follow the instructions given by Police officers and take heed of Police signage and broadcasts at scene.
     
    Special traffic arrangements
    —————————-
     
         The following special traffic arrangements will be implemented by phases, until the crowd has dispersed and the roads are safe for re-opening:
     
    A. Road closure
     
         The following roads will be closed, except for vehicles with permit:
     
    Phase I (from 5pm onwards)
     
    – Salisbury Road and Salisbury Road Underpass between Cheong Wan Road and Kowloon Park Drive;
    – Hung Hom Bypass between Salisbury Road and Metropolis Drive;
    – Hung Hom Bypass between Salisbury Road and Hung Hom Road;
    – Chatham Road South between Granville Road and Salisbury Road;
    – Southbound Chatham Road South between Cheong Wan Road and Granville Road, except for franchised buses and green minibuses (GMBs);
    – Granville Road between Chatham Road South and Science Museum Road, except for franchised buses and GMBs;
    – Canton Road between Gateway Boulevard and Salisbury Road;
    – Southbound Kowloon Park Drive between Gateway Boulevard and Salisbury Road;
    – Northbound Nathan Road between Austin Road and Salisbury Road;
    – Southbound Nathan Road between Granville Road and Salisbury Road;
    – Carnarvon Road between Granville Road and Nathan Road;
    – Hong Wan Path;
    – Mody Lane;
    – Mody Road;
    – Mody Square;
    – Granville Square;
    – Minden Row;
    – Hanoi Road;
    – Bristol Avenue;
    – Minden Avenue;
    – Blenheim Avenue;
    – Hart Avenue;
    – Prat Avenue;
    – Humphreys Avenue;
    – Cameron Road;
    – Cameron Lane;
    – Hau Fuk Street;
    – Middle Road;
    – Peking Road;
    – Lock Road;
    – Hankow Road;
    – Ashley Road;
    – Ichang Street; and
    – Haiphong Road.
     
         During the above road closure period, the following traffic diversions will be implemented:
     
    – Traffic along southbound Hung Hom Road will be directed from Hung Hom Bypass to Cheong Tung Road South roundabout;
    – Traffic along eastbound Metropolis Drive cannot turn right to southbound Hung Hom Bypass;
    – Traffic along southbound Hung Hom Bypass must turn right to westbound Metropolis Drive;
    – Traffic along westbound Cheong Wan Road leading to Chatham Road South must turn right to northbound Chatham Road South or go straight to westbound Austin Road, except for franchised buses and GMBs;
    – Franchised buses and GMBs along southbound Chatham Road South must turn left to eastbound Granville Road;
    – Franchised buses along southbound Nathan Road must turn right to westbound Public Square Street or westbound Jordan Road;
    – Traffic along westbound Jordan Road cannot turn left to southbound Canton Road;
    – Traffic along southbound Canton Road must make a U-turn to northbound Canton Road outside China Hong Kong City;
    – Traffic along northbound Kowloon Park Drive cannot turn left to southbound Canton Road;
    – Traffic along eastbound Salisbury Road must turn left to northbound Kowloon Park Drive;
    – Traffic along northbound Kowloon Park Drive cannot turn right to Peking Road;
    – Granville Road between Nathan Road and Carnarvon Road will be re-routed to one-way eastbound, while traffic along southbound Nathan Road will be instructed to turn left to eastbound Granville Road;
    – Traffic along Science Museum Road cannot turn to Mody Road and Granville Road;
    – Traffic along southbound Salisbury Road near Hong Chong Road will be diverted to Tsim Sha Tsui East; and
    – Traffic along eastbound Granville Road near Chatham Road South must turn left to northbound Chatham Road South.
     
    Phase II (from 5.30pm onwards)
     
    – Northbound Kowloon Park Drive between Salisbury Road and Gateway Boulevard; and
    – Salisbury Road between Canton Road and Kowloon Park Drive.
     
    Phase III (from 6pm onwards)
     
    – Museum Drive;
    – Cultural Drive;
    – The slip road of eastbound Austin Road West at-grade leading to westbound Austin Road West near The Harbourside;
    – The slip road of westbound Austin Road West at-grade leading to eastbound Austin Road West near Xiqu Centre; and
    – The left lane of westbound Austin Road West leading to Austin Road West roundabout.
     
         During the above road closure period, traffic along southbound Nga Cheung Road cannot enter Museum Drive.
     
    Phase IV (from 7.45pm onwards)
     
    – Nga Cheung Road between Jordan Road and Austin Road West;
    – Canton Road between Austin Road West and Kowloon Park Drive;
    – Nathan Road between Jordan Road and Austin Road;
    – Eastbound Bowring Street between Pilkem Street and Nathan Road;
    – Tak Shing Street between Tak Hing Street and Nathan Road;
    – Southbound Nathan Road between Austin Road and Granville Road;
    – Pine Tree Hill Road;
    – Hillwood Road;
    – Carnarvon Road between Kimberley Road and Granville Road;
    – Shun Yee Street;
    – Granville Circuit;
    – Northbound Chatham Road South between Observatory Road and Granville Road;
    – Kimberley Road between Nathan Road and Observatory Road;
    – Kimberley Street; and
    – Granville Road between Nathan Road and Chatham Road South.
     
         During the above road closure period, the following traffic diversions will be implemented:
     
    – Traffic along southbound Nathan Road must turn right to westbound Jordan Road;
    – Traffic along westbound Jordan Road cannot turn left to southbound Nathan Road;
    – Traffic along westbound Austin Road and southbound Cox’s Road cannot turn to Pine Tree Hill Road;
    – Traffic along Observatory Road cannot turn left to westbound Kimberley Street;
    – Traffic along northbound Pilkem Street cannot turn right to eastbound Bowring Street;
    – Traffic along eastbound Bowring Street will be diverted via northbound Pilkem Street;
    – Traffic along southbound Canton Road will be directed to eastbound Austin Road or westbound Austin Road West;
    – Traffic along eastbound Austin Road West cannot turn right to southbound Canton Road;
    – Traffic along westbound Jordan Road heading for Nga Cheung Road will be directed to Kowloon Station Public Transport Interchange;
    – Traffic along westbound Austin Road West will be diverted to northbound Nga Cheung Road elevated road; and
    – Traffic along southbound Nga Cheung Road will be directed to eastbound Austin Road West.
     
    Contingency plan
     
         If necessary, the following roads will be closed:
     
    – Hung Luen Road between Wa Shun Street and Hung Lok Road;
    – Oi King Street; and
    – Kin Wan Street.
     
         During the above road closure period, the following traffic diversions will be implemented:
     
    – Traffic along southbound Hung Luen Road must turn left to eastbound Wa Shun Street;
    – Traffic along westbound Wa Shun Street must turn right to eastbound Hung Luen Road;
    – Traffic along southbound Hung Lok Road cannot turn left to eastbound Hung Luen Road; and
    – Traffic along eastbound Hung Luen Road must turn left to northbound Hung Lok Road.
     
    B. Suspension of bus termini
     
         The Tsim Sha Tsui East (Mody Road) Bus Terminus will be suspended from 5pm.
     
         The Star Ferry Bus Terminus will be suspended from 5.30pm.

         The China Hong Kong City Bus Terminus will be suspended from 7pm.
     
    C. Suspension of parking spaces
     
         All on-street parking spaces, metered parking spaces and motorcycle parking spaces within the closed areas will be suspended from noon to 3am of the following day.
     
    D. Suspension of car parks
     
         During the implementation of the special traffic arrangements, vehicles cannot enter or leave the car parks within the closed road area in Tsim Sha Tsui and West Kowloon Cultural District from 5pm and 6pm respectively, until the roads are safe for re-opening.
     
    Hong Kong Island
    —————-
     
    A. Road closure
     
         Expo Drive East at the north of Expo Drive outside Golden Bauhinia Square, including the pick-up and drop-off areas, will be closed from 3pm.
     
         The following roads will be closed from 5.30pm:
     
    Central District
    —————-
    – Man Kwong Street;
    – Man Fai Street;
    – Man Yiu Street between Man Kwong Street and Man Po Street; and
    – Unnamed Road near Lung Wo Road outside General Post Office metered parking spaces.
     
    Central – Wan Chai Bypass
    ————————-
    – The slip road linking eastbound Central – Wan Chai Bypass to Expo Drive;
    – The slip road linking Lung Wo Road to eastbound Central – Wan Chai Bypass; and
    – The slip road linking westbound Central – Wan Chai Bypass to Lung Wo Road.
     
    Wan Chai
    ——–
    – Eastbound Fenwick Pier Street;
    – Lung King Street;
    – Eastbound Harbour Road;
    – Expo Drive;
    – Expo Drive Central;
    – Expo Drive East;
    – Lung Wo Road between Lung Hop Street and Fleming Road;
    – Lung Tat Path;
    – Convention Avenue;
    – Fleming Road flyover;
    – Fleming Road between Expo Drive East and Harbour Road;
    – Northbound Tonnochy Road between Harbour Road and Hung Hing Road;
    – Southbound Tonnochy Road between Hung Hing Road and Gloucester Road;
    – Marsh Road between Gloucester Road and Hung Hing Road;
    – Marsh Road flyover;
    – Hung Hing Road;
    – Hung Hing Road flyover;
    – Wan Shing Street;
    – Wan Ying Street; and
    – The slip road leading from eastbound Victoria Park Road to Causeway Bay Promenade.
     
         The following roads will be closed from 6.45pm:
     
    Central District
    —————-
    – Yiu Sing Street;
    – Lung Wo Road between Man Yiu Street and Lung Hop Street;
    – Tim Wa Avenue;
    – Legislative Council Road;
    – Tim Mei Avenue;
    – Lung Wui Road;
    – Lung Hop Street;
    – Unnamed road between Harcourt Road and Performing Arts Avenue;
    – Performing Arts Avenue; and
    – Edinburgh Place.
     
    Wan Chai
    ——–
    – Tonnochy Road flyover;
    – Northbound Tonnochy Road between Gloucester Road and Harbour Road;
    – Harbour Drive;
    – Westbound Harbour Road;
    – Northbound Fleming Road between Gloucester Road and Harbour Road;
    – Fenwick Pier Street flyover;
    – Westbound Fenwick Pier Street; and
    – Fenwick Street between Harbour Road and Gloucester Road.
     
    Eastern District
    —————-
    – Watson Road;
    – King Ming Road;
    – Hing Fat Street northward of Whitfield Road;
    – Whitfield Road; and
    – Electric Road between Watson Road and Gordon Road.
     
         The following roads will be closed from 7.45pm:
     
    Central District
    —————-
    – Man Yiu Street between Man Cheung Street and Man Po Street;
    – Man Po Street; and
    – Finance Street between Man Yiu Street and Man Po Street.
     
    Wan Chai
    ——–
    – Lockhart Road and Jaffe Road between Percival Street and Luard Road;
    – Southbound Luard Road between Gloucester Road and Hennessy Road;
    – O’Brien Road;
    – Fleming Road between Jaffe Road and Hennessy Road; and
    – Stewart Road, Tonnochy Road, Marsh Road, Canal Road West and Canal Road East between Gloucester Road and Hennessy Road.
     
    Eastern District (except for franchised buses)
    ———————————————-
    – Westbound Island Eastern Corridor (IEC) between Victoria Park Road and Man Hong Street;
    – The slip roads leading from Healthy Street Central and Tong Shui Road to westbound IEC;
    – The entrance of westbound Central – Wan Chai Bypass Tunnel from IEC.
     
    B. Traffic diversions
     
         In connection with the road closure as mentioned above, the following traffic diversions will be implemented:
     
         From 5.30pm:
     
         Rumsey Street between Chung Kong Road and Connaught Road Central will be re-routed to one-way southbound.
     
         From 7.45pm:
     
    – Traffic along westbound IEC will be diverted via Man Hong Street;
    – Traffic along slip road of Tong Shui Road heading for westbound IEC will be diverted via Wharf Road; and
    – Traffic along eastbound Connaught Road West flyover will be diverted via Finance Street.
     
    C. Suspension of parking spaces
     
         All on-street parking spaces, metered parking spaces and motorcycle parking spaces within the above closed areas will be suspended from 10am, until the roads are safe for re-opening.
     
    D. Suspension of bus termini and public transport interchange
     
         Exhibition Centre Station Public Transport Interchange and Central Ferry Piers Bus Terminus will be suspended from 4.30pm.
     
         Causeway Bay (Whitfield Road) Bus Terminus will be suspended from 6pm.
     
    E. Suspension of car parks
     
         Vehicles parked in car parks within the above closed areas in North Point, Wan Chai and Central District will not be permitted to enter or leave during the road closure period.
     
         If necessary, the car parks on westbound Gloucester Road between Paterson Street and Percival Street will be closed without prior notice.
     
         Police will continue to enforce traffic regulations during the Lunar New Year period. All vehicles parked illegally during the implementation of the above special traffic arrangements will be towed away without prior warning, and may be subject to multiple ticketing. 
     
         Actual implementation of traffic arrangements will be made depending on traffic and crowd conditions in the areas. Motorists are advised to exercise tolerance and patience, and take heed of instructions of the Police on site.      

    MIL OSI Asia Pacific News

  • MIL-OSI United Nations: ‘A Generation Has Been Traumatized’, Says Humanitarian Affairs Chief, Briefing Security Council on Plight of Children in Gaza

    Source: United Nations General Assembly and Security Council

    Meeting a week after a ceasefire paused the war in Gaza, after it raged for almost 470 days, the Security Council discussed the plight of children, with speakers calling for their needs to be prioritized, through the rebuilding of educational infrastructure, the provision of psychosocial support and ensuring a surge of humanitarian aid to the Strip.

    “A generation has been traumatized,” Tom Fletcher, Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator, told the Council, pointing to the United Nations Children’s Fund (UNICEF) finding that 1 million children need mental health and psychosocial support for depression, anxiety and suicidal thoughts. Nonetheless, today’s briefing marks “one of the rare times we are able to highlight positive developments”, he said, with the ceasefire providing a reprieve from relentless hostilities for Palestinians; allowing Israeli hostages and imprisoned Palestinians to be reunited with their families; and allowing a surge in life-saving humanitarian aid into Gaza.  “Children have been killed, starved and frozen to death,” he said, adding:  “Some died before their first breath — perishing with their mothers in childbirth.”  Citing conservative estimates indicating that over 17,000 children are without their families in Gaza, he stated that an estimated 150,000 pregnant women and new mothers are now in desperate need of health services.

    Outlining the UN and its partners’ stepped-up response across the Gaza Strip in recent days to meet the needs of 2 million people across Gaza, he said they were enabled by improved operating conditions, including safe, unobstructed humanitarian access, the absence of hostilities and the almost complete cessation of criminal looting. Such operations included the provision of life-saving services; delivering food parcels and flour and working to reopen bakeries; and distributing fuel to ensure that critical services, such as healthcare and water pumping, can run on back-up generators, he said, underscoring: “At the centre of this, as always, is United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA).”

    He went on to express alarm over the situation in the West Bank, where record-high levels of casualties, displacement and access restrictions witnessed since October 2023 have intensified since the announcement of the ceasefire.  Voicing alarm over attacks by Israeli settlers on Palestinian villages and an ongoing military operation in Jenin causing death and displacement, he urged the Council to ensure the ceasefire is maintained and to ensure that international law is respected across the Occupied Palestinian Territory of Gaza and the West Bank, including East Jerusalem.  Restrictions on critical humanitarian items must be lifted, including items considered to be “dual use”, and there must be accountability for atrocities.  Underscoring the need to ensure humanitarian operations are well-funded, with the 2025 Flash Appeal in need of $4.07 billion to meet the needs of 3 million people in Gaza and the West Bank, he stressed:  “The children of Gaza are not collateral damage”, but deserving of security, education and hope.  “They tell us that the world was not there for them through this war.  We must be there for them now.”

    The Council also heard from Bisan Nateel, from Tamer Institute for Community Education, an organization that helps Palestinian children express themselves through artistic activities, who recounted the “very simple dreams” expressed in drawings by the children she worked with, who “dreamed of going back to school, of playing with friends, and of not hearing constant shelling”.  Instead, she said, they were told to go to the safe place in south Gaza, through a “so-called safe corridor” where their lives were under threat, forced to see bodies along the road, forced to walk as snipers targeted them.  “They arrived unable to say a word about the horrific sights seen in their displacement journey, to a safe area that was targeted,” she said.  Displaying a drawing by a child named Gazi when he was in al-Mawasi refugee camp, in which he drew himself feeling well-fed, at home with his father, she said:  “But Gazi lost his life, along with his father, when their tent was attacked.” Also citing the case of a 12-year-old girl in north Gaza, who saw the remains of relatives “torn to pieces” outside her tent, she said that amidst the horror and violence, the children of the Strip forgot “what it means to live, to be human”.

    Throughout the conflict, she recalled awaiting news of Security Council meetings on the radio, hoping for a ceasefire that would end the massacres.  “Every day we lost our friends, loved ones, our homes and lives,” she said, recalling the death of her friend Mohammed, alongside the children he was drawing and playing with at Al-Maamadani Hospital.  “We used to walk down the streets, not knowing if we would live or die, always waiting for the moment the Council would announce a ceasefire, and end the violations against the Palestinian people, including their right to life, violated during 470 days of continuous attack against Gaza,” she stressed.  She voiced hope that Gazans’ “right to life” will he restored, and that children can go back to school, to play, to draw and to sing; to being “normal children in a normal environment, not surrounded by soldiers, and hearing weapons”.  In Gaza, “we do not know how life looks like in the outside world,” she said, adding:  “We have lost a lot in this war and I hope we will not lose more.”

    MIL OSI United Nations News

  • MIL-OSI Security: Amtrak Employee Admits Participating In $11 Million Health Care Fraud Scheme

    Source: Office of United States Attorneys

    NEWARK, N.J. – An Amtrak employee admitted participating in a health care fraud scheme to defraud Amtrak, Acting U.S. Attorney Vikas Khanna announced.

    Rodolfo Rivera, 41, of Clayton, Delaware, pleaded guilty before U.S. District Judge Madeline Cox Arleo in Newark federal court to an Indictment charging him with conspiracy to commit health care fraud. The Indictment also charges nine other co-conspirators in connection with the scheme: Kevin Frink, 53, of Willingboro, New Jersey; Quinton Johnson, 53, of Irvington, New Jersey; David McBrien, 36, of Levittown, Pennsylvania; Gregory Richardson, 35, of Roosevelt, New York; Michael Toal, 35, of Hazlet, New Jersey; Damany Walker, 41, of Irvington, New Jersey; Timothy Bogen, 59, of Hamden, Connecticut; Dion Jacob, 50, of Brooklyn, New York; and David Lonergan, 64, of Rockaway Park, New York.

    According to documents filed in this case and statements made in court:

    From January 2019 through June 2022, Rivera and his co-conspirators—who were also Amtrak employees—engaged in a scheme to obtain cash kickbacks from health care providers in return for their agreement to allow their health insurance plan to be billed for services that were never provided and were not medically necessary. As a result of the fraudulent claims submitted on behalf of Rivera, his dependent, and other Amtrak employees that he recruited into the scheme, the Amtrak health care plan paid over $2 million in reimbursements. In total, as a result of the conspiracy, the Amtrak health care plan paid over $11 million in fraudulent claims associated with providers connected to the scheme.

    Rivera received thousands of dollars in cash kickbacks from health care providers in return for his participation in the scheme, including from Punson Figueroa, an acupuncturist, and Michael DeNicola, a podiatrist. Figueroa previously pleaded guilty to conspiracy to commit health care fraud and was sentenced on September 24, 2024 to 34 months in prison. DeNicola previously pleaded guilty on June 29, 2022 to conspiracy to commit health care fraud, among other offenses. His sentencing remains pending.

    The health care fraud conspiracy charge carries a maximum potential penalty of 10 years in prison and a $250,000 fine. Rivera’s sentencing is scheduled for June 26, 2025.

    Acting U.S. Attorney Khanna credited special agents of the Amtrak Office of Inspector General, under the direction of Special Agent in Charge Michael J. Waters, the Amtrak Police Department, under the direction of Chief of Police Samuel Dotson, and special agents of the Drug Enforcement Administration, under the direction of Special Agent in Charge Frank A. Tarentino III in New York, with the investigation leading to today’s guilty plea.

    The government is represented by Assistant U.S. Attorneys Jessica R. Ecker and Katherine M. Romano of the Health Care Fraud Unit, and Senior Trial Counsel Barbara Ward of the Bank Integrity, Recovery, and Money Laundering Unit, in Newark.

    The charge and allegations contained in the Indictment against Frink, Johnson, McBrien, Richardson, Toal, Walker, Bogen, Jacob, and Lonergan, are merely accusations, and they are each presumed innocent unless and until proven guilty.

                                                                 ###

    Defense counsel: Dennis S. Cleary, Esq.

    MIL Security OSI